Stockwinners Market Radar for September 07, 2022 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:28 EDT Jury decided Reynolds Vapor's Vuse Alto infringes Altria patents - Altria Group "announces that a jury in the U.S. District Court for the Middle District of North Carolina found that Reynolds Vapor Company's Vuse Alto e-vapor product infringed three patents owned by Altria Client Services. In deciding in favor of Altria, the jury awarded $95.2M in past damages through June 30, 2022. Post-trial proceedings will address ongoing damages through the expiration of Altria's patents in 2035. At trial, Altria urged the jury to find a royalty rate of 5.25%, which the jury accepted in returning its award of past damages."

20:14 EDT Amylyx announces FDA AdCom voted 7 to 2 in favor of approving AMX0035 in ALS - The company states: "Amylyx Pharmaceuticals announced that the FDA Peripheral and Central Nervous System Drugs Advisory Committee, PCNSDAC, voted 7 yes votes and 2 no votes that the available evidence of effectiveness is sufficient to support approval of AMX0035, also known as ursodoxicoltaurine, for the treatment of amyotrophic lateral sclerosis, or ALS. The PCNSDAC's decision was based on a review of all available evidence, including new analyses submitted for discussion at the September 7 meeting and the information presented at the March 30, 2022, PCNS meeting."

19:02 EDT ISPT selects SS&C for performance measurement - SS&C Technologies "announced that ISPT, one of the largest property fund managers in Australia, chose SS&C Sylvan for performance measurement. SS&C Sylvan was selected for its ability to process data automatically, calculate key returns, and provide robust analytical tools."

18:08 EDT Gilead's Trodelvy improves survival in breast cancer study - Gilead announced the positive overall survival - or OS - results from the Phase 3 TROPiCS-02 study evaluating Trodelvy versus comparator chemotherapy in patients with HR+/HER2- metastatic breast cancer who received endocrine-based therapies and at least two chemotherapies. In the study, Trodelvy demonstrated a statistically significant and clinically meaningful improvement of 3.2 months in OS compared to TPC. OS was a key secondary endpoint of the trial. Other key secondary endpoints including objective response rate demonstrated statistically significant improvement in favoring Trodelvy versus TPC. Time to deterioration of Global Health Status/Quality of Life and Fatigue scale per EORTC-QLQ-C30 also favored Trodelvy versus TPC. No statistically significant difference in TTD on the Pain Scale was observed. The safety profile for Trodelvy was consistent with prior studies, with no new safety signals identified in this patient population. The TROPiCS-02 study met its primary endpoint of progression-free survival earlier this year. Trodelvy has not been approved by any regulatory agency for the treatment of HR+/HER2- metastatic breast cancer. Its safety and efficacy have not been established for this indication. Gilead has submitted a supplemental Biologics License Application to the FDA based on data from TROPiCS-02; these data will also be shared with health authorities outside the U.S.

18:06 EDT Exelixis announces Phase 3 COSMIC-313 trial results from ESMO - Exelixis "announced detailed results from COSMIC-313, an ongoing phase 3 pivotal trial evaluating the combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab in patients with previously untreated advanced intermediate- or poor-risk renal cell carcinoma. The data, including detailed results of the primary endpoint of progression-free survival (PFS), are being presented during the Presidential Symposium III on Monday, September 12 at 4:30 p.m. CEST at the 2022 European Society of Medical Oncology (ESMO) Congress. As previously announced, the primary endpoint of PFS per Response Evaluation Criteria in Solid Tumors version 1.1, as assessed by Blinded Independent Radiology Committee (BIRC), demonstrated that cabozantinib in combination with nivolumab and ipilimumab significantly reduced the risk of disease progression or death compared with the combination of nivolumab and ipilimumab. At a prespecified interim analysis for the secondary endpoint of overall survival , the combination of cabozantinib, nivolumab and ipilimumab versus the combination of nivolumab and ipilimumab did not demonstrate a significant benefit. Therefore, the trial will continue to the next analysis of OS."

18:02 EDT Trupanion acquires Smart Paws, terms not disclosed - Trupanion announced the acquisition of Smart Paws GmbH, a rapidly-growing pet insurance provider with operations in Germany and Switzerland, on August 31. "Continental Europe is a highly attractive opportunity for Trupanion, offering high per capita spending and relatively low levels of pet insurance penetration. Through the acquisition of Smart Paws, we look forward to expanding our footprint in other key European countries," said Simon Wheeler, EVP of International at Trupanion. "In addition to being strategically positioned geographically in the European Union, the Smart Paws team brings expertise within the region's veterinary industry, which will be integral to building our presence in that market." The Smart Paws team will continue to manage and administer all of their products and membership policies and will be a part of Trupanion's international organization led by Simon Wheeler. The company does not expect any material financial impact to its 2022 financial results as a result of the acquisition. The financial terms of the transaction were not disclosed.

17:47 EDT Biogen announces NEJM publication of phase 2 study of litifilimab in SLE/CLE - The company states: "Biogen announced that The New England Journal of Medicine, NEJM, has published a second manuscript detailing positive results from the company's two-part Phase 2 LILAC study, which evaluated litifilimab, an investigational drug, in systemic lupus erythematosus, or SLE, and cutaneous lupus erythematosus, or CLE. Results from the SLE portion of the study published today show litifilimab met the study's primary endpoint by significantly reducing total active joint count compared to placebo. Positive data from the CLE portion of the study were published in NEJM on July 28th, 2022. Biogen is currently enrolling participants into the Phase 3 TOPAZ-1 and TOPAZ-2 studies, which will evaluate the efficacy and safety of litifilimab in participants with active SLE at 269 clinical trial sites worldwide. As part of Biogen's commitment to delivering diversity in its clinical trials, enrollment targets have been set in the TOPAZ studies to achieve appropriate representation of the African American and Hispanic/Latino communities. Biogen also plans to initiate a pivotal study of litifilimab in CLE in 2022. In Part A of LILAC, litifilimab significantly reduced the total number of swollen and tender joints in participants with SLE from baseline compared to placebo over 24 weeks. This Phase 2 trial was not powered to assess secondary endpoints. In Part A, litifilimab was generally well tolerated, with most reported adverse events (AEs) rated as mild or moderate. The most common AEs reported in greater than or equal to5% of participants in the pooled litifilimab groups were diarrhea, nasopharyngitis, urinary tract infection, fall and headache. "

17:38 EDT Bit Digital earned 145.3 Bitcoins in August, up 2% month-over-month - Bit Digital announced its unaudited bitcoin and Ethereum production and corporate updates for the month of August 2022. In August 2022, the Company earned 145.3 bitcoins, a 2% increase compared to the prior month. The Company earned 0 ETH during August 2022 compared to 0.5 in the month ending July 31, 2022. Treasury holdings of BTC and ETH were 919.2 and 3,684.0 with a fair market value of approximately $18.4 million and $5.7 million, respectively, on August 31, 2022. The Company owned 38,594 bitcoin miners and 731 Ethereum miners as of August 31, 2022, with an estimated maximum total hash rate of 2.7 Exahash ("EH/s") and 0.3 Terahash ("TH/s), respectively. During the month, the Company purchased 561 M30s miners and sold 103 M21 miners. During the month of August, the Company continued to work with hosting partners to deploy miners. 29% of its currently-owned fleet, or 11,545 bitcoin miners and 0 ETH miners representing 1.04 EH/s and 0 TH/s, respectively, was deployed in North America as of August 31, 2022. The Company's ETH miners remain offline due to previously announced interruptions to certain hosting partners' operations.

17:11 EDT Casey's General Stores still sees FY23 SSS up 4%-6% - Still sees inside margin of 40%. Expects to add approximately 80 stores in fiscal 2023, and expects to exceed our stated three year commitment of 345 units.

17:07 EDT Emirates to end partnership with JetBlue on October 30 - The company states: "Our partnership with JetBlue Airways ends on 30 October 2022." Reference Link

17:00 EDT ManTech stockholders approve acquisition by Carlyle - ManTech International Corporation (MANT) announced that its stockholders approved a proposal to adopt the merger agreement entered into between the company and Carlyle (CG) at a Special Meeting of Stockholders held on September 7, 2022. As previously announced, under the terms of the transaction, ManTech stockholders will receive $96.00 per share in cash. "We thank our stockholders for their strong support of this transaction," said ManTech Chairman, Chief Executive Officer and President Kevin M. Phillips. "We look forward to completing the transaction with Carlyle to deliver immediate and premium value to our stockholders, stronger outcomes for our customers and more opportunities for our employees." The closing of the proposed transaction remains subject to certain customary closing conditions. Pending satisfaction of such conditions, the transaction is expected to close during the week of September 12, 2022.

16:46 EDT 22nd Century COO Michael Zercher to depart, - 22nd Century announced changes in its management team as the company accelerates growth in its reduced nicotine content tobacco business. The company announced that Michael Zercher, president and COO, will depart the company effective September 30. John Miller, who leads 22nd Century's tobacco business team, will assume the tobacco-related duties of the COOs role, while CEO James Mish will assume the title of corporate president.

16:34 EDT DBV Technologies initiates Phase 3 study for peanut allergy in children - DBV Technologies announced the initiation of the Phase 3 VITESSE study using the modified Viaskin Peanut Patch, in peanut-allergic children ages 4 to 7 years. The study was initiated following exchanges with the FDA. The protocol has been submitted to study sites for subsequent Institutional Review Boards/Ethics Committees approval. The first patient screened is expected in Q4 2022 with the last patient screened by year-end 2023. The company anticipates that the topline results will read out in Q1 2025. DBV and the FDA have engaged in ongoing discussions. These interactions determined that VITESSE will evaluate the efficacy and safety of the modified Viaskin Peanut patch as a peanut allergen immunotherapy, which may potentially support a future BLA submission. The primary efficacy endpoint is the percentage of treatment responders in the active versus placebo arms at month 12. VITESSE will also evaluate the safety of the modified Viaskin Peanut patch based on overall adverse events, local site reactions and systemic allergic reactions.

16:30 EDT One Group Hospitality announces $10M share repurchase authorization - The ONE Group Hospitality announced that its Board of Directors has authorized the commencement of a share repurchase program for up to $10 million of its outstanding common stock. "We have the strategies in place to be a differentiated leader in the upscale and polished casual segments and are highly confident in our long-term growth opportunities," said Emanuel "Manny" Hilario, President and CEO of The ONE Group. "This $10 million repurchase authorization enhances our ability to create value for shareholders and is made possible by our balance sheet strength and commitment to disciplined capital allocation."

16:27 EDT Asana jumps 10% after Q2 earnings beat and guidance raise

16:24 EDT Altice USA names Dennis Mathew as CEO - Altice USA "announces that its Board of Directors has appointed Dennis Mathew to the position of CEO, effective October 3, 2022. Mr. Mathew assumes the CEO role from Dexter Goei who has been named Executive Chairman of the Board of Directors, also effective October 3, 2022. All of Mr. Goei's direct reports will report to Mr. Mathew on the effective date. Founder and current Chairman of the Board, Patrick Drahi, will remain a Director of the Board."

16:24 EDT U.S. Xpress backs FY22 capital expenditures view roughly $150M - U.S. Xpress Enterprises said it is experiencing an increase in insurance and claims expense as claim settlements have accelerated and courts work to clear the backlog of cases which were delayed during the pandemic. Based on the quarter-to-date, the Company expects approximately $15.0 million in additional insurance and claims expense, primarily driven by one large claim, in its third quarter financial results as compared to its 2022 second quarter financial results. The Company continues to expect capital expenditures, net of proceeds to be approximately $150.0 million for 2022. However, the Company is targeting net capital expenditures of less than $100 million for 2023 as it implements a revised trade cycle management initiative and reduces software development costs. The 2023 net capital expenditure expectation assumes scheduled deliveries and trades for the balance of 2022 remain on schedule. The Company continues to expect $18 million of interest expense for the full year 2022.

16:23 EDT Live Oak Bancshares to invest $25M, add 204 jobs over next five years - Live Oak Bank committed to adding 204 jobs over the next five years and investing $25M in campus expansions thanks in part to three investment grants given by the State of North Carolina, New Hanover County and the city of Wilmington. The state and local grants, totaling more than $2M, are expected to be received over 5 to 12 years. Live Oak intends to hire employees with an average salary of more than $101,000. Newly created positions will include analysts, underwriters, lending staff, technology managers, information security professionals and other personnel. This creates more than $20M in annual payroll impact for the region.

16:22 EDT American Eagle says demand trends remain difficult QTD - The company said, "Quarter-to-date, demand trends remain difficult, with brand revenue down in the high-single digits following exceptional growth and a record Back-to-School season last year. Assuming current trends continue, the third quarter gross-margin rate would be in the mid-30s and fourth quarter in the low-30s. This reflects higher markdowns in anticipation of a more promotional retail environment and the company's seasonal clearance cadence which is more weighted to the fourth quarter. Management has expanded expense cuts with a focus on store payroll, corporate expense, professional services and advertising. These actions are now expected to drive $100 million in annualized expense reductions to plan, compared to our prior target of $60 million. This translates to SG&A dollars remaining relatively flat to last year in the second half, compared to prior guidance for low-to-mid-single digit growth."

16:19 EDT Toll Brothers, Equity Residential team on Dallas-Fort Worth rental communities - Toll Brothers (TOL) through its Toll Brothers Apartment Livin rental division, and Equity Residential (EQR), announced plans to develop three new luxury rental communities totaling 1,053 units in the Dallas-Fort Worth metropolitan area. These projects represent the first three joint ventures under the strategic relationship that Toll Brothers and Equity Residential established in 2021. Through the partnership, the parties initially intend to focus on selectively acquiring and developing sites for apartment rental communities in specific metro markets, including Dallas-Fort Worth, where both parties have a significant or growing presence. Under the partnership, Equity Residential has committed to invest 75% of the equity for each selected project and Toll Brothers will invest 25%. It is expected that each project will also be financed with approximately 60% leverage. Equity Residential will have the option to acquire each property upon stabilization. The parties have targeted an initial minimum co-investment of approximately $750 million in combined equity, or nearly $1.9 billion capacity, assuming 60% leverage.

16:17 EDT Erasca announces preliminary ERAS-007, ERAS-601 data - Erasca announced preliminary Phase 1/1b monotherapy data for ERK1/2 inhibitor ERAS-007 and SHP2 inhibitor ERAS-601 in BRAF-driven and RAS/MAPK-altered solid tumors. A retrospective pooled analysis of all trials evaluating ERAS-007 or ERAS-601 in advanced solid tumors was performed that included Erasca's ongoing HERKULES-1 and FLAGSHP-1 trials and Asana BioSciences' previously completed ASN007-101 trial. The analysis was designed to identify responsive subsets that were particularly sensitive to ERAS-007 or ERAS-601 for prioritized combination development within indications of high unmet medical need where no approved targeted therapies are available. Patients with solid tumors with RAS/MAPK alterations were segmented into two groups based on differing levels of responsiveness to monotherapy inhibition and differences in RAS/MAPK pathway reactivation: patients with colorectal cancer, or CRC, and two patients with non-CRC. Key findings from the retrospective pooled interim analysis of ERAS-007 and ERAS-601 include: 23% of patients with RAS/MAPK-altered non-CRC solid tumors responded to single agent ERAS-007 or ERAS-601; 44% with a subset of BRAF-driven non-CRC solid tumors responded to single agent ERAS-007 or ERAS-601; ERAS-007 and ERAS-601 had favorable safety and tolerability monotherapy profiles with largely non-overlapping treatment-related adverse events that are expected to be monitorable and manageable at the likely recommended combination doses.

16:12 EDT GameStop forms partnership with FTX - GameStop announced that it has entered into a partnership with FTX US. The partnership is intended to introduce more GameStop customers to FTX's community and its marketplaces for digital assets. In addition to collaborating with FTX on new ecommerce and online marketing initiatives, GameStop will begin carrying FTX gift cards in select stores. During the term of the partnership, GameStop will be FTX's preferred retail partner in the United States. The financial terms of the partnership are not being disclosed.

16:09 EDT Dave & Buster's provides update on first five weeks of Q3 - The company said, "The Company's business has continued to improve through the first five weeks of the third quarter, during which comparable store sales on a consolidated basis increased 22.1% with increases of 17.6% at Dave & Buster's branded stores and 42.3% at Main Event branded stores compared with the same period in 2019. Consolidated walk-in comparable store sales increased 24.7% while Special Event comparable store sales declined 4.2% for the five-week period compared with 2019. At Dave & Buster's branded stores, walk-in comparable store sales increased 20.0% while Special Event comparable store sales declined 11.9% for the five-week period compared with 2019. At Main Event branded stores, walk-in comparable store sales increased 48.9% while Special Event comparable store sales increased 9.3% for the five-week period compared with 2019."

16:05 EDT Health Catalyst announces new leadership appointments in strategic areas - Health Catalyst announced three new leadership assignments in support of its strategic focus areas moving forward. This strategic focus includes the appointment of the company's current Chief Revenue Officer, Kevin Freeman, as Chief Growth Officer, and current Chief Brand and Communications Officer, Tarah Neujahr Bryan, as Chief Marketing Officer, effective September 7. Kevin Freeman came to Health Catalyst in 2020 as part of the Vitalware acquisition. Tarah Neujahr Bryan joined Health Catalyst in 2013 and has served as Editorial Director, Senior Vice President of Marketing, and Chief Brand and Communications Officer. Prior to joining Health Catalyst, Tarah served as the Marketing Communications Director and the Foundation Executive Director at a community hospital, managed at an advertising agency, was the Editor and Operations Manager at an archaeology firm, and provided triage assistance and patient admissions at a Level-II Trauma Center. Health Catalyst has also named Dave Ross, current Associate Chief Technology Officer, as Chief Technology Officer, also effective September 7. Dave Ross joined Health Catalyst in 2021 as part of the Twistle acquisition, and was previously the Chief Technology Officer and Co-Founder of Twistle, leading all product development and engineering activities for over ten years prior to Twistle being acquired by Health Catalyst.

15:31 EDT Globalstar reverses lower, down 3% in late-day trading - Shares of Globalstar (GSAT), which had been higher after the stock reopened for trading, are now down 6c, or 3%, to $2.03 near 3:30 pm ET.

15:01 EDT Verizon announces 'One Unlimited for iPhone' - Verizon (VZ) announced it is introducing "One Unlimited for iPhone," which it calls the "only plan that gets you Apple One, including Apple Music, Apple TV+, Apple Arcade and iCloud+ - all shareable with your whole family." Verizon stated: "Starting at just $50 per line, per month for four lines with Auto Pay and paper-free billing, plus taxes and fees, get up to $480 in annual value for your whole family with One Unlimited for iPhone and a connected device. Get Apple One individual plan with single-line accounts and Apple One Family for accounts with two or more lines that lets you share private Apple One access with up to five other family members. Plus, with up to 50% off connected device plans, new and existing customers can add an Apple Watch or iPad to their account and enjoy their Apple favorites and One Unlimited for iPhone across all devices."

14:50 EDT Globalstar up 17% after confirming Apple satellite partnership - Shares of Globalstar (GSAT) have resumed trading and are up 35c, or 17%, to $2.44 after the company disclosed that partner Apple (AAPL) announced new satellite-enabled services for certain of its products and that Globalstar will be the satellite operator for the services.

14:37 EDT Apple says Fitness+ available to iPhone users in 21 countries later this fall - Apple announced that Apple Fitness+, its fitness and wellness service, will be available for all iPhone users to subscribe to, even if they don't have an Apple Watch. "The update will be available later this fall in all 21 countries where the service is offered. On Monday, September 12, Fitness+ will introduce the fourth season of Time to Walk featuring new guests, including award-winning actor Regina Hall, Latin Grammy winner Nicky Jam, and Emmy Award-winning performer Leslie Jordan. Time to RunSM will kick off its second season exploring new locations such as Yellowstone National Park in Wyoming, Mexico City, and Queenstown, New Zealand. That same day, Fitness+ will also launch the latest Artist Spotlight series with workouts featuring the music of Mary J. Blige, The Rolling Stones, and The Weeknd," Apple said.

14:35 EDT Apple says second generation AirPods Pro available on September 9 - Apple announced the second generation of AirPods Pro, the most advanced AirPods ever. "With the power of the new H2 chip, AirPods Pro unlock breakthrough audio performance - including major upgrades to Active Noise Cancellation and Transparency mode - while also offering a unique way to experience Spatial Audio that's even more immersive." AirPods Pro will be available to order online and in the Apple Store app starting Friday, September 9, with availability in stores beginning Friday, September 23.

14:33 EDT Apple announces Apple Watch Series 8, Apple Watch SE - Apple introduced Apple Watch Series 8 and the new Apple Watch SE. Apple Watch Series 8 features the design of Apple Watch, including a large, Always-On Retina display and a strong crack-resistant front crystal. "With all-day 18-hour battery life, Apple Watch Series 8 builds on best-in-class health and safety features like the ECG app and fall detection by introducing temperature-sensing capabilities, retrospective ovulation estimates, Crash Detection, and international roaming. The new Apple Watch SE delivers the core Apple Watch experience, including Activity tracking, high and low heart rate notifications, and Emergency SOS, as well as the new Crash Detection feature and a completely redesigned back case that perfectly matches the three classic case finishes, all at a more affordable price of $249." Both models are powered by watchOS 9.

14:21 EDT Iridium falls 7% to $43.82 after Globalstar partners with Apple

14:14 EDT Apple says iPhone 14 Pro comes with 'Dynamic Island' - Says iPhone 14 Pro comes with Dynamic Island, which comes at the top of the screen and expands to fit the nature of any alert or notification. Says Dynamic Island always live and active.

14:12 EDT Globalstar to abandon Duplex assets with Apple partnership - As previously disclosed, Globalstar (GSAT) has been evaluating the continuation of second-generation Duplex services in light of other potential uses for the company's capacity, such as those within the partnership agreements. In early 2021, the company terminated its second-generation Duplex services to support extended testing of the services to a partner; however, such termination was considered temporary unless or until the partner announced its intent to proceed with launch of the services. Due to this shift in strategy triggered by today's Apple (AAPL) announcement, Globalstar intends to abandon its second-generation Duplex assets, including gateway property, prepaid licenses and royalties, and inventory totaling approximately $175M.

14:08 EDT Globalstar says will be satellite operator for Apple satellite-enabled services - In a regulatory filing, Globalstar (GSAT) disclosed that on September 7, Apple Inc. (AAPL), which the company identifies as its "partner," announced new satellite-enabled services for certain of its products. Globalstar will be the satellite operator for the services pursuant to the terms agreement first disclosed in the company's Form 10-K for the year ended December 31, 2019, and certain related ancillary agreements. The services constitute the potential service described in the company's previous disclosure about the terms agreement, Globalstar said in the filing. "Since execution of the Terms agreement, the parties have completed several milestones including (i) a feasibility phase, (ii) material upgrades to Globalstar's ground network to enhance redundancy and coverage, (iii) construction of 10 new gateways around the world, (iv) the successful launch of the ground spare satellite, and (v) rigorous in-field system testing. The Partnership Agreements generally require Globalstar to allocate network capacity to support the Services and provide for the inclusion of Globalstar's Band 53/n53 in Partner's cellular-enabled devices that use the Services, for use by third parties, subject to certain terms and conditions. It is currently expected that Partner will make the Services available to customers during the fourth quarter of 2022. There is no assurance that the Service Launch will occur or, if it does occur, that the Services and the revenues and other consideration expected to be received under the Partnership Agreements will be fully realized or will continue," the filing stated.

14:03 EDT Globalstar halted for news as Apple discusses iPhone satellite connectivity - Apple (AAPL) said during its launch event that iPhone 14 comes with new safety features, including Emergency SOS via satellite. Globalstar (GSAT) shares have been halted for trading, news pending, while Apple continues its iPhone launch event.

13:53 EDT Globalstar trading halted, news pending

13:49 EDT Apple unveils iPhone 14, 14 Plus - Says new iPhones come with larger displays.

13:47 EDT Veru says FDA Advisory Committee to review sabizabulin EUA request on Oct. 6 - Veru announced that the U.S. Food and Drug Administration has informed the company that FDA's Pulmonary-Allergy Drugs Advisory Committee will meet to discuss the company's request for Emergency Use Authorization of sabizabulin for hospitalized COVID-19 patients at high risk for ARDS. The meeting is scheduled for October 6. "The FDA has now completed the audits of selected Phase 3 clinical sites in the United States and now Brazil and Bulgaria and no deficiencies were reported to us. The FDA informed us today that they intend to convene an Advisory Committee Meeting to discuss the emergency use authorization for sabizabulin. We are looking forward to advancing the regulatory review process for the use of sabizabulin for the treatment of hospitalized moderate to severe COVID-19 patients at high risk for ARDS," said Mitchell Steiner, M.D., Chairman, President, and CEO of Veru.

13:42 EDT Apple announces Apple Watch Ultra, priced at $799 in U.S. - Apple announced Apple Watch Ultra, which it said "brings a new bold design and a wide range of features built for endurance, exploration, and adventure." Apple said: "Apple Watch Ultra introduces a 49mm titanium case and flat sapphire front crystal that reveals the biggest and brightest Apple Watch display yet. A customizable Action button offers instant access to a wide range of useful features. Apple Watch Ultra has the best battery life of any Apple Watch, reaching up to 36 hours during normal use.1 Additionally, a new low-power setting, ideal for multi-day experiences, can extend battery life to reach up to 60 hours.2 The Wayfinder watch face is designed specifically for the larger Apple Watch Ultra display and includes a compass built into the dial, with space for up to eight complications." Customers in Australia, Canada, France, Germany, India, Japan, the UAE, the U.K., the U.S., and more than 40 other countries and regions can order Apple Watch Ultra today, with availability in stores beginning Friday, September 23. Apple Watch Ultra is priced at $799 in the U.S.

13:35 EDT GE Aviation opens Asia-Pacific Service Center in Australia - GE Aviation announced the opening a new facility in Australia to provide maintenance, repair and overhaul services for customers across the Asia-Pacific region. The new $8M Asia-Pacific Service Centre at Brisbane Airport positions GE Aviation to support more customers and expand its presence across the region. The facility will be the largest GE Aviation, Systems service centre in the Asia-Pacific region. The facility supports avionics, flight management, electrical power and DOWTY propeller systems on various aircraft including the Boeing 737 and 787, Q400 and F-50 regional aircraft and the Royal Australian Air Force's fleet of C-130J Super Hercules and C-27J Spartan Military Transport Aircraft.

13:33 EDT North American rail traffic up 5.3% for the week ending September 3 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending September 3, as well as volumes for August. U.S. railroads originated 1,189,892 carloads in August 2022, up 2.3%, or 27,040 carloads, from August 2021. U.S. railroads also originated 1,335,618 containers and trailers in August 2022, down 1.2%, or 15,856 units, from the same month last year. Combined U.S. carload and intermodal originations in August 2022 were 2,525,510, up 0.4%, or 11,184 carloads and intermodal units from August 2021. Total U.S. weekly rail traffic was 513,087 carloads and intermodal units, up 3.7% compared with the same week last year. Total carloads for the week ending September 3 were 241,431 carloads, up 5.7% compared with the same week in 2021, while U.S. weekly intermodal volume was 271,656 containers and trailers, up 2.1% compared to 2021. North American rail volume for the week ending September 3 on 12 reporting U.S., Canadian and Mexican railroads totaled 339,416 carloads, up 6.3% compared with the same week last year, and 365,087 intermodal units, up 4.5% compared with last year. Total combined weekly rail traffic in North America was 704,503 carloads and intermodal units, up 5.3%. North American rail volume for the first 35 weeks of 2022 was 23,701,811 carloads and intermodal units, down 2.5 percent compared with 2021. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC), Union Pacific (UNP)Trinity Industries (TRN), Greenbrier (GBX), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

13:28 EDT Apple unveils Apple Watch Ultra - Says Apple Watch Ultra comes with 49mm titanium case, new customizable Action Button, 36 hours of basic battery life, 60 hours of battery life in new battery optimization set to come later this fall. Says Ultra has "most technical" watchface yet, called "wayfinder."

13:22 EDT Apple unveils new second-generation Apple Watch SE - Says new SE comes in midnight, silver, starlight colors. Says new SE 20% faster than previous Apple Watch SE, still comes with motion sensors for Crash Detection.

13:19 EDT Apple says Watch Series 8 starts at $399, available September 16 - Says Series 8 available in four standard colors and three stainless steel finishes. Says Watch Series 8 priced at $399 for GPS edition and $499 for GPS + Cellular edition. Says preorders start today for September 16 launch date.

13:13 EDT Apple Watch Series 8 comes with new advanced cycle tracking features - Says Series 8 introduces suite of advanced cycle tracking features for people who get periods. Says Series 8 comes with new, more effective temperature sensor. Says Series 8 health features will come with improved privacy protection. Says Series 8 capable of estimating ovulation dates and spotting cycle deviations.

13:08 EDT Apple unveils Apple Watch Series 8 - Says Apple Watch top selling smartwatch globally for seven years running. Says Series 8 features brighter display that extends right to the edge of the frame. Says Series 8 is swim proof, dust proof, and crack resistant. Comments taken from September 7 Apple Event livestream.

12:21 EDT Match Group CFO: Guidance set at level 'we think we can achieve' - CFO Gary Swidler says the company's new CEO wants to "be successful and beat guidance and perform well out of the gate." Comments taken from Evercore TMT Conference.

12:07 EDT Immix Biopharma complets GMP manufacturing of scaled-up batch of IMX-110 - Immix Biopharma announced that it has completed Good Manufacturing Practice manufacturing of a scaled-up batch of IMX-110 for clinical trials. IMX-110 was produced using proprietary, scaled-up manufacturing process that will provide drug supply for 2 ImmixBio clinical trials planned to start in 2022: first, planned monotherapy IMX-110 clinical trial in soft tissue sarcoma; second, planned combination IMX-110 + BeiGene anti-PD-1 tislelizumab clinical trial in advanced solid tumors.

12:00 EDT Wiley falls -13.3% - Wiley is down -13.3%, or -$6.16 to $39.95.

12:00 EDT AMTD Digital falls -15.7% - AMTD Digital is down -15.7%, or -$10.82 to $58.13.

12:00 EDT Glaukos rises 19.5% - Glaukos is up 19.5%, or $9.40 to $57.50.

11:47 EDT YouTube TV now supports 5.1 audio on Apple TV, Fire TV devices - Yesterday, Alphabet's (GOOGL) YouTube TV announced that the service now supports 5.1 audio on Apple TV (AAPL) and Amazon Fire TV (AMZN) devices for compatible content. "If you're a game console user, we're working on getting this available to you as soon as possible, and will share live updates here," the company said. Reference Link

11:39 EDT Essential Utilities halts discussions with BCWSA on potential acquistion - Essential Utilities, earlier this summer, announced its subsidiary, Aqua Pennsylvania, Inc., had signed an exclusivity agreement with the Bucks County Water and Sewer Authority to continue discussions for a potential acquisition. Yesterday those discussions were halted in light of statements by the Bucks County commissioners and BCWSA board chairman. "While we were surprised and disappointed by the sudden turn of events yesterday, we respect the opinions of the Bucks County elected officials and have offered to remain a resource to them. The professionalism of the staff at the BCWSA was exemplary and we hope to continue those collegial relationships as we work together to solve the water and sewer challenges in our region," said Essential Chairman and CEO Christopher Franklin. "We continue to have a strong pipeline of opportunities and continue to find elected officials interested in potential partnerships across our multi-state footprint. In light of some of the tragic events associated with long-term deferred maintenance in government owned systems across the country, we remain committed to providing viable solutions to water and sewer utilities."

11:22 EDT AT&T CFO notes some moderation in inflation in fuel, labor

11:15 EDT AT&T still seeing 'solid' customer demand, says CFO

11:12 EDT Vuzix says Toppan uses smart glasses in RemoPick system - Vuzix Corporation announced that Toppan is using Vuzix smart glasses in its RemoPick system, which is currently being trialed at a 7-11 store in Iizuna, Japan.

10:47 EDT Cineworld Group to continue to operate cinemas "as usual" amid Chapter 11 - The company said, "During the restructuring process, Cineworld expects to operate its global business and cinemas as usual without interruption. In conjunction with the filing of the Chapter 11 cases, the Group Chapter 11 Companies have filed certain customary "first day" motions to obtain the requisite court authority for the Group to continue operating its businesses in the ordinary course without disruption to its customers, vendors, suppliers or employees as much as practicable. The Group Chapter 11 Companies intend to pay all vendors and suppliers in full and on normal terms for valid amounts for goods and services received during the Chapter 11 process. In addition, the Group expects that employees will continue to receive their usual wages and benefits without interruption. Cineworld has secured commitments for an approximate $1.94B debtor-in-possession financing facility provided by certain existing lenders, which will be used to, among other things, fund the Group's operations and refinance certain prepetition funded indebtedness. Subject to Court approval, the DIP financing, together with the Group's available cash reserves and cash provided by operations, is expected to provide sufficient liquidity for Cineworld to meet its ongoing obligations, including post-petition obligations to vendors and suppliers, as well as employee wages, salaries and benefits programs. Cineworld and its brands around the world - including Regal, Cinema City, Picture House and yes Planet - are continuing to welcome customers to cinemas as usual, which will not change during the Chapter 11 cases. The Group expects to continue to honour the terms of all existing customer membership programs, including Regal Unlimited and Regal Crown Club in the United States and Cineworld Unlimited in the UK."

10:31 EDT Shuttle Pharmaceuticals Inc trading resumes

10:25 EDT SpringWorks Therapeutics trading resumes

10:17 EDT Tecogen receives multiple unit order from energy company - Tecogen announces an order for five Tecopower cogeneration units from a subsidiary of a multi-billion dollar Energy Services Company. The units are expected to be installed within the proximity of Tecogen's factory service centers, which are expected to provide long-term service of the units.

10:03 EDT SpringsWorks Therapeutics expands global collaboration with GSK - SpringWorks Therapeutics (SWTX) entered into an expanded global, non-exclusive license and collaboration agreement with GSK (GSK) for nirogacestat, SpringWorks' investigational oral gamma secretase inhibitor, in combination with Blenrep, GSK's antibody-drug conjugate targeting B-cell maturation antigen. Under the terms of the expanded agreement, SpringWorks will receive a $75M equity investment from GSK, with shares of common stock priced at a premium to the 30-day volume-weighted average share price on September 2, 2022. SpringWorks will also be eligible to receive up to $550M in additional payments based on reaching certain development and commercial milestones. SpringWorks will retain full commercial rights to nirogacestat and will be responsible for global commercialization of nirogacestat.

10:02 EDT Amylyx says stock halted for second FDA Advisory Committee meeting on AMX0035 - Amylyx Pharmaceuticals announced that Nasdaq has halted trading of the company's common stock. The second meeting of the U.S. Food and Drug Administration's Peripheral and Central Nervous System Drugs Advisory Committee, or PCNSDAC, is occurring today to review the New Drug Application for AMX0035, also known as ursodoxicoltaurine, for the treatment of amyotrophic lateral sclerosis, or ALS. The Advisory Committee meeting is scheduled for 12:00 p.m. ET. The PCNSDAC previously met on March 30, 2022 to discuss the NDA for AMX0035 for the treatment of ALS. The Prescription Drug User Fee Act, or PDUFA, target action date for the NDA is September 29, 2022.

10:00 EDT AMTD Digital falls -12.7% - AMTD Digital is down -12.7%, or -$8.76 to $60.19.

10:00 EDT UiPath falls -17.0% - UiPath is down -17.0%, or -$2.65 to $12.95.

10:00 EDT Glaukos rises 12.2% - Glaukos is up 12.2%, or $5.88 to $53.98.

10:00 EDT Azure Power rises 13.9% - Azure Power is up 13.9%, or 50c to $4.09.

09:55 EDT Amylyx Pharmaceuticals trading halted, news pending

09:52 EDT SpringWorks Therapeutics trading halted, news pending

09:47 EDT Equinor falls -6.8% - Equinor is down -6.8%, or -$2.57 to $35.11.

09:47 EDT UiPath falls -19.7% - UiPath is down -19.7%, or -$3.07 to $12.52.

09:47 EDT Glaukos rises 7.6% - Glaukos is up 7.6%, or $3.66 to $51.76.

09:40 EDT Addentax Group Corp trading resumes

09:38 EDT Sunrise New Energy announces $11.3M order from CATL - Sunrise New Energy announced that its joint venture graphite anode manufacturing company has received an order valued at $11.3M from EV battery manufacturer CATL. The company believes that it will ship the products out before the end of 2022. The company had already received an order from CATL valued at $8.4M and delivered earlier in the year, bringing the total orders from this customer to over $19.7M up from zero in 2021.

09:33 EDT Blue Apron amends RJB investment agreement to raise $56.5M vs. $50M initially - In a regulatory filing, the company states: "As previously described on Blue Apron Holdings Form 8-K as filed on August 8, 2022, on August 7, 2022, the Company entered into Amendment No. 1 to the Purchase Agreement, which amended the Purchase Agreement entered into between the Company and RJB Partners LLC, an affiliate of Joseph N. Sanberg, an existing holder of the Company's Class A common stock, on April 29, 2022 pursuant to which, among other things, RJB agreed to purchase from the Company on August 31, 2022, or such other date as may be agreed to by the Company and RJB, (i) the 1,666,667 shares of Class A common stock that RJB agreed to purchase from the Company under the Original Purchase Agreement on the Closing at a price of $5.00 per share instead of $12.00 per share and (ii) an additional 8,333,333 shares of Class A common stock at a price of $5.00 per share, for an aggregate of 10,000,000 shares of Class A common stock for an aggregate purchase price of $50.0M (or $5.00 per share) on the Closing . On September 7, 2022, the Company and RJB entered into that certain Amendment No. 2 to Purchase Agreement , pursuant to which the Company and RJB mutually agreed (a) to extend the Closing of the Private Placement under the Purchase Agreement to September 30, 2022 or such earlier date as may be agreed to by the Company and RJB, and (b) to change the per share price to $5.65 for 10,000,000 shares of Class A common stock, for an aggregate purchase price of $56.5M."

09:32 EDT SoFi Technologies enters multi-year partnership with Los Angeles Chargers QB - SoFi announced a three-year partnership with Los Angeles Chargers Quarterback Justin Herbert. Herbert will also receive equity stake and appears in SoFi's new brand campaign and television spot, where he breaks up with bad banking and moves on with SoFi.

09:30 EDT Citrix says received all regulatory approvals, deal to close later this month - In a regulatory filing, Citrix Systems disclosed that it has received all regulatory approvals required under the previously announced agreement and plan of merger, dated January 31, 2022, by and among the company, Picard Parent, Inc., Picard Merger Sub, Inc., and, for certain limited purposes detailed in the merger agreement, TIBCO Software, pursuant to which merger sub will merge with and into the company, with the company surviving the merger as a wholly-owned subsidiary of parent. As a result, the condition to closing the merger in respect of clearances under antitrust and foreign investment laws has been satisfied. As of the date of this report, the company expects the merger to close during the last week of September 2022, subject to satisfaction of the remaining customary closing conditions.

09:26 EDT G Mining Ventures closes $116M private placement financing - G Mining Ventures announced that it has closed the second and final tranche of its non-brokered private placement financing announced on July 18, 2022. Under the first and second tranches of the Placement, the Corporation issued an aggregate of 189,066,765 common shares at C$0.80 per share for aggregate gross proceeds to GMIN of C$151.3 million. The funds will be used for the development and construction of its 100% owned Tocantinzinho Gold Project. Pursuant to the Second Tranche, the Corporation issued 29,004,265 GMIN common shares at a price of C$0.80 per share to La Mancha Investments S.a r.l. for gross proceeds of C$23.2 million. The common shares sold pursuant to the Second Tranche are subject to a hold period which will expire on January 8, 2023 in accordance with applicable Canadian securities laws. La Mancha acquired such common shares for investment purposes. In the future, La Mancha may, from time to time, increase or decrease its investment in GMIN through market transactions, private arrangements, treasury issuances or otherwise. Closing of the first tranche of the Placement took place on July 22, 2022, pursuant to which the Corporation issued 160,062,500 common shares at a price of C$0.80 per share for gross proceeds of C$128.1 million. Following the closing of the First Tranche and prior to the closing of the Second Tranche, La Mancha held 82,875,000 common shares of GMIN, which represented approximately 19.8% of GMIN's then outstanding common shares, For additional details regarding the Placement, please refer to the news releases of the Corporation dated July 18, 2022 and July 22, 2022 available on the GMIN website as well as the SEDAR profile of the Corporation on www.sedar.com. Following the closing of the Second Tranche, La Mancha holds 111,879,265 common shares of GMIN, which represent approximately 25.0% of GMIN's outstanding common shares, and the holdings of Eldorado Gold Corporation and Franco-Nevada Corporation now total 17.7% and 9.9%, respectively. Members of the Gignac Family, along with GMIN directors and officers, are collectively the fourth largest shareholder holding 7.8% of GMIN's outstanding common shares. In connection with the Placement, the Corporation and the Investor entered into an investor rights agreement granting the Investor certain director nomination, anti-dilution, and registration rights, and which is further described in the news release of the Corporation dated July 18, 2022. Pursuant to the terms of the IRA, the Investor has partially exercised its right to nominate two directors to the board of the Corporation by nominating Mr. Karim-Michel Nasr, who has been appointed to the Board. A second nominee will follow at a later date.

09:17 EDT Terreno Realty acquires $7.3M industrial property in California - Terreno Realty acquired an industrial property in Anaheim, California on September 6 for a purchase price of approximately $7.3M. The 1.2-acre improved land parcel at 3091 East Coronado Street is adjacent to the intersection of CA SR 91 and CA SR 57. The property was acquired vacant. Further, Terreno Realty Corporation has executed a lease for the property commencing immediately and ending December 2027 with a Southern California investment group facilitating commissary services, resulting in an estimated stabilized cap rate of 5%.

09:16 EDT Alkaline Water announces initial orders from warehouse club chain - Alkaline Water announced that another membership-only warehouse club chain has placed initial orders for the Alkaline88 1-gallon 4 pack to be sold in 48 of its east-coast clubs.

09:12 EDT Black Knight's Optimal Blue adds ICE Mortgage Rate Lock to CompassPoint - Black Knight announced the addition of ICE Mortgage Rate Lock Index Futures within CompassPoint, the leading risk management and loan sale platform offered by Optimal Blue, a division of Black Knight. This expanded suite of futures will help lenders better manage their interest rate risk by offering new techniques for hedging conforming and jumbo mortgage loans and mortgage servicing rights. "We work with hundreds of clients every day to hedge the interest rate risk of mortgage pipelines, and we're excited to bring yet another innovation to the market that helps our lenders avoid basis risk and additional transaction costs when hedging certain mortgage loans," said Scott Happ, president of Optimal Blue, a division of Black Knight. "While the to-be-announced marketplace is very effective at hedging the majority of our lenders' pipelines, the addition of the ICE Mortgage Rate Lock Index Futures with CompassPoint will deliver expanded support for hedging mortgage servicing rights, jumbo loans or loans with extended lock terms."

09:11 EDT Mitsubishi UFJ expands direct lending team - Mitsubishi UFJ Financial announced the expansion of its newly formed Direct Lending business with the hiring of Claude Mattessich and Will McCarthy. Both Mattessich and McCarthy have joined the bank as Managing Directors and Senior Originators. Mattessich will be based in New York City, while McCarthy will be based in Chicago. Both will report to Christopher Freeman, Managing Director, in the Direct Lending group. With nearly 30 years of professional experience, Mattessich joins MUFG from CIT Bank. McCarthy joins MUFG from LBC Credit Partners, where he was part of the Middle Market Leveraged Finance Group.

09:10 EDT Freshpet announces organizational changes - Freshpet announced several changes in its organizational structure designed to strengthen the company's capabilities in production, quality, engineering, logistics and finance. Those leadership changes include: CFO Heather Pomerantz has announced her intention to step down to pursue other opportunities effective September 7. While the Company searches for her replacement, current Vice Chairman and previous Freshpet CFO Dick Kassar will serve as Interim CFO. Pomerantz's resignation did not result from any disagreement with the company concerning any matter relating to the Company's financial reporting, policies or practices. Executive VP of Manufacturing, Steve Weise, whose intention to retire was announced previously, will remain with the company in a consulting role through 2023 to support improvements in the company's quality assurance systems and other components of the Company's manufacturing and supply chain. Jay Dahlgren, previously VP of Operations at J.M. Smucker Company, is now serving as a consultant to the company with a focus on mitigating manufacturing and supply chain risks. VP of Manufacturing, Ricardo Moreno, will be appointed Senior VP of Manufacturing & Engineering. The company expects to backfill the VP of Manufacturing role as it builds out this important area of its operations. Senior VP of Engineering Michael Hieger will broaden his responsibilities to include all capital expansion projects and engineering resources and will report to Moreno.

09:09 EDT Sidus Space signs launch agreement with SpaceX for five launches - Sidus Space announced that it has signed a launch agreement with SpaceX for five launches, beginning in early 2023. Sidus Space has designed and is manufacturing LizzieSat, for its multi-mission LEO satellite constellation operating in diverse orbits as approved by the International Telecommunication Union in February 2021. LizzieSat is in advanced stages of development and offers many differentiating attributes. Specifically, LizzieSat satellites fly custom payloads tailored to maximize customer return on investment; Sidus manufactured 3D printed satellites maximize customer volume within a lightweight bus; redundant attitude controls systems provide precision pointing for payloads; and propulsion maintains satellite orbit and provides collision avoidance capability. The launches will support previously announced contracts with NASA and Mission Helios as well as prospective customers that Sidus continues to layer into its pipeline in all areas including payload hosting and capturing space-based data.

09:08 EDT Medical Properties Trust re-leases Watsonville Community Hospital - Medical Properties Trust announced that it has successfully re-leased its Watsonville Community Hospital in Watsonville, California to Pajaro Valley Health Care District and has sold certain facilities to Prime Healthcare pursuant to a tenant purchase option. In late August, Pajaro acquired the operations of Watsonville Community Hospital following a relatively short bankruptcy process. As part of this transaction, MPT was repaid more than $30M in financing it provided to allow the hospital to remain open to host tens of thousands of emergency department visits, admit thousands of patients and facilitate thousands of surgeries since the default of the original operator. Also, in early September, MPT sold to Prime nine general acute hospitals and two related medical office buildings in California, Indiana, Nevada and Pennsylvania for net proceeds of roughly $360M. Proceeds from both of these transactions, as well as roughly $200M of loan repayment proceeds expected as the result of LifePoint Health's planned acquisition of a majority interest in Springstone in the first half of 2023, will combine to provide MPT approximately $600M in near-term liquidity to reduce leverage and execute select accretive acquisitions. Furthermore, the impact of the Watsonville and Prime transactions is fully considered in MPT's previously communicated per share estimates of full-year 2022 net income and normalized funds from operations.

09:08 EDT UPS begins recruiting 100,000+ seasonal workers - UPS will hire more than 100,000 seasonal employees ahead of the holiday rush. The company is filling full- and part-time seasonal positions - primarily seasonal delivery and CDL drivers, package handlers, and driver helpers - by offering competitive wages across multiple shifts in hundreds of locations across the country. Permanent positions also are available in some areas.

09:07 EDT Perficient acquisition of Inflection Point seen as immediately accretive to EPS - Perficient announced the acquisition of Inflection Point Systems, an approximately $15M revenue software consulting and product development firm with nearshore operations based in Monterrey, Mexico, and headquarters in Columbia, Maryland. The acquisition is not reflected in existing 2022 revenue or earnings guidance and is expected to be accretive to adjusted earnings per share immediately. "We're excited to continue to strengthen our nearshore delivery capacity, enhance our digital capabilities, and further expand across Latin America with the strategic acquisition of Inflection Point," said Jeffrey Davis, Perficient's Chairman and CEO. "Our multi-shore, fully-integrated, global delivery approach continues to be a key driver of growth, and a compelling differentiator in the market.

09:06 EDT Figs down 4% as Spruce Point makes short call, sees up to 60% downside - Shares of Figs Inc. are down 42c, or 4%, to $10.62 in pre-market trading after Spruce Point released a short report on the company, which it calls "a COVID-19 beneficiary that will fail to sustain momentum due to demand normalization and increasing competition." The short-selling firm, which believes Figs' co-founders are "prone to exaggerating their professional work history and key business and financial metrics," argues that "the history of retail stocks shows that revenue growth slowdowns are a harbinger for multiple compression. The firm sees up to 45%-60% downside risk to $4.40-$6.05 per share.Reference Link

09:05 EDT CNH Industrial president, North America Brad Crews to retire - CNH Industrial announces that Brad Crews, President North America, has indicated his intention to retire. Mr. Crews is a longstanding member of the Company's Senior Leadership Team and is also the leader of the North American Agricultural Segment. During 2023, Brad will focus on a new role, supporting Derek Neilson, President Agriculture, by spearheading various strategic initiatives. Mr. Crews will retain his current responsibilities until his replacement as President, North America, is announced.

09:04 EDT Crypto Company's BTA launches new offering, inks deal with Polkadot - The Crypto Company announced that its wholly owned education and consulting subsidiary, Blockchain Training Alliance has launched a new service offering - which will leverage its expertise in blockchain technology to prepare educational resources for engineers looking to build on the Polkadot platform. The launch of the service offering is paired with the announcement that BTA has signed an agreement with decentralized web 3.0 blockchain interoperability platform pioneer Polkadot for the development of an educational program designed to give engineers the necessary tools to work within the platform framework.

09:03 EDT DraftKings taps The Miz, Tony Hawk for responsible gaming ad campaign - DraftKings announced its newest responsible gaming initiative - the Practice Safe Bets advertising campaign - as the Company marks the American Gaming Association's inaugural Responsible Gaming Education Month this September. Produced by DraftKings' creative and media agency VaynerMedia, the campaign includes two commercials - the first featuring professional wrestler The Miz and the second featuring legendary skateboarder Tony Hawk - that emphasize the importance of engaging in responsible gaming, including setting limits on play by using the responsible gaming tools available on the DraftKings app. The spots will air in radio and TV markets across the U.S., as well as on DraftKings' various social media channels.

09:03 EDT Getty Images renews partnership with Amazon.com - Getty Images (GETY) has renewed its partnership with Amazon (AMZN) that sees Getty Images' collection of sports, news, entertainment, archival and creative images integrated in Amazon's Alexa services and products and its Fire TV software stack.

08:52 EDT CEL-SCI says Multikine reduced and eliminated tumors - CEL-SCI Corporation issued the following letter to its shareholders. "The Phase 3 study of our investigational cancer immunotherapy, Multikine , was the largest advanced primary head and neck cancer study ever conducted. We built a full-scale manufacturing facility and spent 10 years and over $100M because we were convinced that our Multikine could help these very sick patients. Our successful results are unprecedented for a disease that has not seen a survival benefit from treatment in decades. Multikine Reduced and Eliminated Tumors Within Three Weeks and Before Surgery The most important result of our study is this: 16% of Multikine patients in the radiation-only group in our Phase 3 study had at least a 30% tumor reduction within just a few weeks of treatment before surgery. Five of these responders had their tumors completely disappear before surgery. Think about that for a minute. These patients presented with advanced primary disease, and within three weeks of Multikine treatment, before surgery, their tumors were gone. "

08:47 EDT Orbit's Electronics Group reports August bookings in excess of $2.1M - Orbit International announced that its Electronics Group, reported bookings in excess of $2,100,000 for the month of August 2022. In addition, inclusive of Orbit's Power Group, consolidated bookings reached approximately $2,900,000 for the month. Deliveries for certain of these orders have already commenced and are expected to continue through the second quarter of 2023

08:41 EDT Zentek enters manufacturing, supply agreement with Viva Healthcare Packaging - Zentek announces it has entered into a Manufacturing and Supply Agreement with Viva Healthcare Packaging to manufacture and sell surgical masks enhanced with Zentek's proprietary ZenGUARD antimicrobial coating. During the pandemic, VMedCare quickly became one of the leaders in surgical mask manufacturing in Canada with production of between 15 and 20 million units per month. The partnership between Zentek and VMedCare will create a fully "Made in Canada" source of ZenGUARD-enhanced masks for the Canadian market. Under the Agreement, Zentek will provide ZenGUARD-coated spunbond material to VMedCare, who will be responsible for manufacturing and packaging the ZenGUARD surgical masks. Zentek and VMedCare's combined sales teams will work together to secure sales of the ZenGUARD-enhanced surgical masks.

08:39 EDT Biote enters strategic partnership with IMAC Holdings - Biote (BTMD) has entered into a partnership with IMAC (BACK). Through this partnership, IMAC will add certain Biote services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures.The company has begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September.

08:38 EDT Biotricity wins NIH grant for AI-enabled real-time monitoring, predictive analyt - Biotricity announced that it will be carrying out an NIH-sponsored Phase I study of Bioflux-AI, Biotricity's innovative artificial intelligence-driven system of real-time monitoring and prediction technology, in subjects with Chronic Kidney Disease. The risk of ischemic and hemorrhagic stroke is 5 to 30 times higher in patients with CKD and has a mortality rate of up to three times that of the general population. Effective stroke risk prediction is currently flawed in CKD patients because comorbidities often remain undiagnosed and stroke risk stratification schemes do not consider stages of CKD. Additionally, the detection of stroke-risk variations due to dialysis requires real-time risk monitoring, which is unavailable to date.

08:36 EDT Truist Financial names Mike Maguire as chief financial officer - Truist Financial announced that Mike Maguire, Truist's chief consumer finance and payments officer, has been named chief financial officer, CFO, effective Sept. 15. Maguire succeeds current Truist CFO Daryl Bible, whose retirement was announced in May and who will remain at Truist during a transition period. Maguire will continue to serve as a member of Truist's executive leadership team reporting to Chairman and Chief Executive Officer Bill Rogers and will oversee accounting, tax, treasury, financial planning and analysis, investor relations and other responsibilities from the bank's Charlotte, North Carolina, headquarters.

08:36 EDT XS Financial provides CAPEX lease facility to Ascend Wellness - XS Financial announced that it has provided a $15M lease facility to Ascend Wellness Holdings, a multi-state, vertically integrated cannabis operator focused on bettering lives through cannabis. AWH has been approved for a $15M CAPEX lease facility to purchase new equipment with up to 60-month terms. This facility will be used for cultivation, manufacturing and processing equipment across Massachusetts, Illinois, and New Jersey.

08:35 EDT Biote announces strategic partnership with IMAC Holdings - biote Corp. (BTMD) announced that it has entered into a partnership with IMAC Holdings (BACK) a regenerative rehabilitation company focused on treating musculoskeletal and neurodegenerative disease. Through this partnership, IMAC will add certain Biote services to its network of outpatient clinics that deliver orthopedic, regenerative, and advanced, non-surgical medical procedures. "As leaders in hormone optimization and regenerative health and wellness, respectively, we believe Biote and IMAC are well-positioned to make an exponential impact on the lives of individuals who are hoping to live fuller, pain-free, and healthy lives through all stages of aging. We are honored to embark on this strategic partnership with a company whose mission aligns so well with ours," said Terry Weber, Biote Chief Executive Officer. "We believe the future is incredibly bright for Biote, IMAC, and all those who will benefit from our partnership.""We are excited to add Biote's services to IMAC clinics, which will be used to implement innovative weight loss and hormone optimization therapy within our current patient population," said Jeff Ervin, IMAC Founder and Chief Executive Officer. "Where IMAC has a focus on evidence-based regenerative applications, Biote brings a similar focus to hormone optimization which we see as a complementary service line to our existing patient base. We believe the Biote Method will be a powerful treatment tool for our clinics to help alleviate certain aspects of obesity, which is a leading cause of chronic illness and back pain."The Company has begun training IMAC medical professionals in the Biote Method for launching the treatments at select IMAC Regeneration Centers in September.

08:34 EDT Bristow awarded multi-year award from Equinor for search, rescue services - Bristow Group (VTOL) announced an award from Equinor (EQNR) to provide search and rescue services offshore at the Johan Sverdrup and Statfjord B platforms, located in the Norwegian North Sea off the west coast of Norway. A critical part of the emergency preparedness on the southern Norwegian continental shelf, the contract has a duration of four years and includes three single year extension options. Three advanced search and rescue configured S-92 helicopters will provide the search and rescue service. Two helicopters will be based on Equinor's platforms with a backup S-92 based onshore. "We are honoured that Equinor has placed their trust in Bristow. This award is a strong declaration of their confidence in our industry-leading experience in providing search and rescue services," said Heidi Wulff Heimark, Managing Director of Norway. "Search and rescue is a strategically important service for Bristow, and we are all extremely proud to be chosen as the preferred operator for SAR services to Equinor's emergency preparedness with SAR helicopters located offshore at Statfjord B and Johan Sverdrup offshore installations and backup SAR."

08:33 EDT Genasys announces new Emergency Management and Zonehaven software contracts - Genasys announced multi-year Genasys Emergency Management software-as-a-service contracts from Pinal County, Arizona and the Housing Authority of New Orleans, and a Zonehaven software contract from the University of California, Irvine. GEM delivers emergency notifications through multiple channels, including voice calls, SMS, email, desktop alerts, social media, IPAWS, and other delivery systems, to help ensure critical communications are received before, during, and after crisis situations. Zonehaven reduces evacuation time from hours to minutes by incorporating hyperlocal knowledge to model evolving disasters and the subsequent impact on evacuation zones, traffic patterns, and public safety.

08:31 EDT Privia Health to partner with OhioHealth Health System - Privia Health announced a non-binding memorandum of understanding to form a strategic partnership and launch a medical group for independent providers throughout the state of Ohio. The partnership is subject to the negotiation and execution of definitive agreements by both parties. The partnership is expected to support the growth and enhance the performance of OhioHealth's existing clinically integrated network. Privia Health and OhioHealth are expected to provide a new alternative for Ohio physicians and provider groups that choose to remain independent and care for patients across all payment models as they move into value-based care arrangements. New providers are expected to join the new medical group and access the Privia technology and services platform to leverage its data connectivity through a breadth of interoperable solutions and population health expertise to reduce administrative burden, enable care insights and collaboration. Upon execution of the agreements, the new medical group is expected to participate exclusively in OhioHealth's CIN and Accountable Care Organization for access to value-based arrangements.

08:26 EDT Candel Therapeutics appoints Jason Amello as CFO, Garrett Nichols as CMO - Candel Therapeutics has named Jason Amello as CFO and Garrett Nichols as the Chief Medical Officer or CMO. Amello is joining Candel effective September 21, and is replacing current CFO John Canepa, who has decided to pursue other interests and spend more time with his family. Amello comes to Candel from Saniona AB, a rare disease biotech company where he served as CFO. Previously, Amello was Senior VP, CFO, and Treasurer of Akebia Therapeutics. Prior to joining Akebia, he was Executive VP, CFO and Treasurer of Ziopharm Oncology. Nichols joins the company from Istari Oncology, an oncolytic viral immunotherapy company where he was CMO. Prior to that he had a career at GlaxoSmithKline. He was Head of Clinical Development at ViiV Healthcare, a pharmaceutical company specializing in the development of therapies for HIV infection, and CMO at Chimerix.

08:24 EDT PetVivo appoints Paula Wittler as Western Business Development Manager - PetVivo Holdings announced that Paula Wittler has accepted a position with the Company as its new Business Development Manager for the Western Region of the United States.She has served in various roles in product promotion, product distribution, technical sales and marketing with veterinary companies such as Zoetis Animal Health.

08:22 EDT Oxford Lane estimates NAV per share $5.69-$5.79 as of August 31 - Management's unaudited estimate of the range of the NAV per share of our common stock as of August 31, 2022 is between $5.69 and $5.79. This estimate is not a comprehensive statement of our financial condition or results for the month ended August 31, 2022. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending September 30, 2022 may differ materially from this estimate, which is given only as of August 31, 2022. As of August 31, 2022, the Company had approximately 156.4 million shares of common stock issued and outstanding.

08:22 EDT VNET Group announces change in registrant's certifying accountant - VNET Grou announced the appointment of KPMG Huazhen as the Company's independent registered public accounting firm, effective September 7, 2022, succeeding Ernst & Young Hua Ming, E&Y, the Company's former independent registered public accounting firm. The change of the Company's independent registered public accounting firm was made after careful consideration and evaluation process and was approved by the audit committee of the board of directors of the Company. E&Y has served as the Company's independent registered public accounting firm since 2010. On August 16, 2022, the Company notified E&Y of its intention to dismiss E&Y. E&Y's audit reports on the Company's consolidated financial statements as of and for the years ended December 31, 2020 and 2021 did not contain an adverse opinion or disclaimer of opinion and were not qualified or modified as to uncertainty, audit scope or accounting principles. On September 7, 2022, the Company dismissed E&Y. The Company is working closely with E&Y and KPMG to ensure a seamless transition

08:20 EDT Harmonic introduces new Single Illumination System - Harmonic announced it will introduce a new Single Illumination System, SIS, offering to ensure greater interoperability and cost savings for broadcast operators with digital terrestrial television, DTT, and direct-to-home, DTH, services. "Our new SIS solution optimizes DTT and DTH distribution over satellite and offers a one-stop-shop solution for DVB-SIS, including transmission and reception," said Stephane Cloirec, vice president of video appliance products at Harmonic. "Our software solution provides operators a flexible, scalable and cost-effective approach for increasing viewer engagement by including regional channels in DTT offerings."

08:20 EDT VirTra receives orders worth $9.0M from two federal agencies - VirTra has received two orders worth approximately $9.0M under an existing contract with the U.S. Customs and Border Protection. Of the total order amount, $4.3M is attributable to the CBP and $4.7M is attributed to another U.S. federal agency ordered under the same contract. The orders consist of VirTra's flagship V-300 and portable V-100 simulators, recoil kits and magazines, V-Threat-Fire devices and other accessories. Service plans are included as well as training and installation. Items on the orders are expected to be delivered within the next eight months.

08:18 EDT Mindset Pharma files national patents protecting Family 1 application - Mindset Pharma announced the filing of 16 different national applications for the protection of one of four of the Company's key Families of novel, next-generation psychedelics with differentiated characteristics. Included within these applications are several drug candidates that the Company classifies as belonging to "Family 1", which are described as second-generation psilocybin analogs, with potential improvements in effect size, safety, safety, and manufacturing compared to psilocin and psilocybin. Mindset's Family 1 scaffold includes the first elected Mindset clinical candidate, MSP-1014, which is the Company's most advanced drug candidate, a psilocybin-like chemical entity that has the potential to be a best-in class psychedelic treatment, and more effective alternative. MSP-1014 has demonstrated improved efficacy, with reduced potential side effects, and safety profile compared to the first-generation drug candidate, psilocybin, in preclinical studies. Mindset filed national applications in 16 different countries altogether, including the principal South East Asian markets. In order to further broaden its intellectual proprety portfolio, Mindset has also recently filed another provisional application with the USPTO applying a new elegant chemical structural strategy to Family 1, which has never been explored before, to enhance its overall intellectual property moat around Family 1 candidates. The Company is pleased to announce that it has granted options to purchase an aggregate of 200,000 common shares of the Company exercisable at a price of $0.55 per share and expiring on September 6, 2023, to an investor relations consultant of the Company.

08:18 EDT Teva: Patient who used ProAir Digihaler boost weekly number of SABA-free days - Teva Pharmaceuticals announced that full results from the CONNECT1 study evaluating the ProAir Digihaler , albuterol sulfate, Inhalation Powder and the Digihaler System in the management of asthma patients compared to standard of care albuterol reliever therapy, were published online ahead of print in The Journal of Allergy and Clinical Immunology: In Practice. The study found patients who used the ProAir Digihaler had reductions in weekly average daily short-acting beta agonist inhalations and an increase in weekly number of SABA-free days. In addition, patients in the ProAir Digihaler group had a higher number of discussions with physicians around adherence and inhaler technique prompted by the objective data provided by ProAir Digihaler versus patients who used SoC albuterol inhalers. "Asthma remains one of the most common and challenging chronic health conditions in adults and children, many of whom have poorly-controlled disease leading to increased symptoms, exacerbations and healthcare resource utilization. Asthma management is complicated, and overuse and misuse of rescue medications is a common problem that contributes to poor asthma control," said Flavia C.L. Hoyte, M.D., Associate Professor of Allergy and Immunology at National Jewish Health in Denver, Colorado, and University of Colorado Hospital, Aurora, Colorado. "This study highlights the potential of a digital health tool to support asthma management and physician-patient interactions and discussions around inhaler technique and adherence, as recommended by asthma guidelines."

08:17 EDT Aemetis finalizes $7B of supply contracts with airlines - Aemetis announced that $7 billion of sustainable aviation fuel and renewable diesel supply agreements have been signed with 10 airlines for a total of 916 million gallons of blended SAF, including a contract with Cathay Pacific that was signed by Aemetis today. Previously, Aemetis announced a contract with a major travel stop chain for 450 million gallons of renewable diesel. The combined value of the 10 airline contracts, including incentives, is approximately $3.8 billion. The airline supply agreements provide for the delivery of SAF over a seven-to-ten year time period. Airline customers include Delta Air Lines, Jet Blue Airlines and oneworld Alliance members American Airlines, Alaska Airlines, British Airways, Cathay Pacific, Finnair, Iberia, Japan Airlines and Qantas.

08:15 EDT Metals Company subsidiary receives ISA recommendation to begin collection test - Metals Company announced that the International Seabed Authority has completed its review of the Environmental Impact Statement and Environmental Monitoring and Management Plan submitted by its subsidiary, Nauru Ocean Resources or NORI, and recommended that it proceed with its forthcoming collector test. The conclusion of the International Seabed Authority's review process allows NORI to proceed with its planned integrated pilot collection system trials in its NORI-D exploration contract area in the Clarion Clipperton Zone of the Pacific Ocean. NORI's offshore strategic partner Allseas will test a system consisting of a prototype nodule collector at the seafloor and the riser system to bring nodules to the surface production vessel, Hidden Gem. Approximately 3,600 tons of polymetallic nodules are expected to be collected during the trial beginning later this month with an expected conclusion in Q4. The data collected, together with many terabytes of existing baseline data collected by NORI throughout 16 offshore campaigns, will form the basis of NORI's application to the International Seabed Authority for an exploitation contract.

08:14 EDT Sensus Healthcare adds Mohammad Khan to Medical Advisory Board - Sensus Healthcare announces the addition of Mohammad K. Khan, M.D., Ph.D. to its Medical Advisory Board. This appointment increases the size of the Sensus Medical Advisory Board to 10 professionals. Dr. Khan is a world-renowned physician scientist who currently serves as Professor of Medicine in the Department of Radiation Oncology at the Emory University School of Medicine.

08:12 EDT Kraft Heinz updates long-term net leverage target ratio to three times - The company said, "Kraft Heinz is committed to providing stockholders with a strong return of capital and given current circumstances plans to prioritize its deployment of capital to: maintain its current attractive dividend, invest in the organic business to support brands and profitable growth, pay down debt, maintain commitment to investment grade, pursue accretive acquisitions and/or repurchase shares and further increase dividends, subject to the approval by the Board of Directors. The Company has updated its long-term net leverage target ratio from consistently below four times to approximately three times. With interest rates 100% fixed with a weighted average maturity of 14.5 years, and leverage meaningfully improved, the Company believes this level will provide Kraft Heinz with a strong balance sheet through cycles and sufficient financial flexibility."

08:12 EDT Agios Pharmaceuticals announces resignation of CFO Jonathan Biller - Agios Pharmaceuticals disclosed that on September 6, Jonathan Biller notified the company of his intention to resign as Chief Financial Officer, head of corporate affairs and principal financial officer of the company, effective September 16, in order to pursue other opportunities.

08:11 EDT Kraft Heinz highlights long-term financial targets - The company's previously announced long-term algorithm reflects this accelerated growth profile with targeted: organic net sales growth of 2% to 3%; adjusted EBITDA growth of 4% to 6% and adjusted EPS growth of 6% to 8%. The company plans to drive organic net sales growth of 2% to 3% through its three strategic pillars of growth, each anticipated to contribute approximately one percentage point of growth with the following targets: North America Zone Retail representing approximately two-thirds of total company organic net sales and growing approximately 1% to 2%, in line with pre-pandemic industry growth. Foodservice representing roughly 15% of total company organic net sales and growing mid-to-high single digits. Emerging Markets Retail, within the Company's International Zone, representing approximately 10% of total company organic net sales and growing double digits. Adjusted EBITDA growth of 4% to 6% is expected to be driven by organic net sales growth, gross margin expansion enabled primarily by anticipated gross efficiencies of nearly 3% per year, and flat overhead as a percentage of organic net sales, while increasing marketing by approximately one percentage point over time, as a percentage of organic net sales. The expected adjusted EBITDA growth, along with expectations of declining interest expense, partially offset by anticipated increasing depreciation, is expected to drive 6% to 8% adjusted EPS growth. The company is now targeting to maintain capital expenditures at approximately 4% of organic net sales and generate free cash flow conversion at approximately 100%. "We have successfully completed two phases of our ongoing transformation - resetting our foundation and implementing our operating model," said Patricio. "With the right people, portfolio and capabilities in place, we now look ahead to accelerating profitable growth. Achieving greatness will also include a focus on personalized marketing and a strong emphasis on innovation. I am excited about what we have accomplished so far and how it positions us for the future, but we still have work to do."

08:10 EDT Cloopen regains compliance with NYSE minimum price requirement - Cloopen Group announced that, based on a notification letter the Company received from the New York Stock Exchange, NYSE, on September 1, 2022, the Company has regained compliance with the NYSE's continued listing standard for minimum share price. On May 31, 2022, the NYSE notified the Company that it was not in compliance with the NYSE's continued listing standards because, as of May 27, 2022, the average closing price of the Company's American depositary shares was less than US$1.00 per ADS over a consecutive 30 trading-day period. On September 1, 2022, the Company received a confirmation from the NYSE that a calculation of the Company's average ADS price for the 30-trading days ended August 31, 2022 indicated that the Company's ADS price was above the NYSE's minimum requirement of US$1.00 based on a 30-trading day average. Accordingly, the Company is no longer considered below the US$1.00 continued listing criterion. As a result, the Company has regained compliance within the prescribed time, and the ADSs will continue to be traded on the NYSE, subject to the Company's continued compliance with all applicable continued listing standards.

08:09 EDT Farmmi continues North American sales expansion with latest order - Farmmi announced the Company is continuing its North American sales expansion with its latest order, complementing growth in the Company's new corn and cotton businesses. The order for Winter mushrooms and Camellia mushrooms will export to Canada. Yefang Zhang, Farmmi's Chairwoman and CEO, commented "We are focused on driving growth as we leverage the strong platform we built in our core fungi business, with the significant new greenfield revenue opportunities we recently added in corn and cotton. These are all established, very large markets where our brand, logistics and supply chain expertise, warehousing and processing and fulfilment capabilities give Farmmi a meaningful competitive advantage. Food scarcity has increasingly been at the forefront of concerns for many of our customers as they work to secure much needed inventory during global drought conditions and continuing COVID concerns. Our team is doing a great job supporting this added demand and working closely with our customers to align with their expected growth over the coming quarters. We also continue to prioritize the geographic markets we are focusing our resources on, with North America remaining one of the highest growth potential markets for us after our domestic China market and the broader Asian market."

08:08 EDT Edgewise gets FDA authorization for EDG-5506 trial for DMD treatment - Edgewise Therapeutics announced that the U.S. Food and Drug Administration has authorized a clinical trial of EDG-5506 in children with DMD. The Company expects to begin dosing participants in the LYNX Phase 2 trial in the fourth quarter of 2022. EDG-5506 is an investigational orally administered small molecule myosin modulator designed to protect injury-susceptible fast skeletal muscle fibers in dystrophinopathies such as DMD and Becker muscular dystrophy . "This is an important achievement for our team as we seek to expand our studies with EDG-5506 into individuals with DMD. Our team has worked with key opinion leaders and patient advocacy groups to thoughtfully design our LYNX Phase 2 clinical trial," said Joanne Donovan, M.D., Ph.D., Chief Medical Officer of Edgewise. "The promising tolerability and changes in biomarkers of muscle damage that we have seen in studies with EDG-5506 in individuals with BMD supports our next step of expanding enrollment to individuals with DMD." The LYNX Phase 2 trial is a placebo-controlled trial to assess the effect of three doses of EDG-5506 over 12 weeks on safety, pharmacokinetics and biomarkers of muscle damage. Approximately 27 children with DMD aged 4 to 9 years on stable corticosteroids are expected to be enrolled at up to 12 sites across the United States. Participants will then continue in an open-label extension part of the trial for a total of 12 months to gain further insights into safety and functional measures. Importantly, this trial is designed to identify the doses of EDG-5506 that have the potential to reduce biomarkers of muscle damage and provide functional benefit to patients in a Phase 3 trial. "As observed in many neuromuscular disorders, we need to have complementary approaches to address the underlying cause of the condition," said Pat Furlong, Founding President and Chief Executive Officer, Parent Project Muscular Dystrophy. "By Edgewise expanding from Becker to Duchenne, this adds hope for those affected by Duchenne."

08:07 EDT Brickell Biotech announces corporate rebranding to Fresh Tracks - Brickell Biotech announced that it has changed its name to Fresh Tracks Therapeutics. The new name, logo, website, and branding elements were introduced to reflect the company's evolution into a clinical-stage pharmaceutical company aiming to disrupt existing treatment paradigms by developing innovative and differentiated prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases. The Company's common stock will begin trading under the new Nasdaq ticker symbol "FRTX" on September 8, 2022. The introduction of the Fresh Tracks Therapeutics brand is designed to represent the Company's fresh vision and development strategy. The unveiling of the Company's rebranding reinforces its commitment to develop novel therapies in immunology and inflammation, its path toward strategic growth, and a renewed corporate strategy. Scientific Advisory Board. In connection with the rebrand to Fresh Tracks Therapeutics, the Company announced the formation of a Scientific Advisory Board consisting of renowned scientists and clinicians with deep experience across immunology and inflammation, including Drs. Kate Fitzgerald, Bernard Khor, Pui Lee, Peter Nigrovic, and Bridget Wagner. The SAB will provide expertise and guidance to the FRTX management and Board of Directors as the Company develops its novel pipeline of differentiated therapies for the treatment of autoimmune and inflammatory diseases, including FRTX-02, FRTX-10, and next-generation kinase inhibitor platform.

08:06 EDT COMSovereign announces departures of chairman, CEO Hodges, President Howell - COMSovereign announced that the Board of Directors of COMSovereign has accepted the resignation of co-founder, Chairman and CEO Daniel Hodges, effective September 1, 2022. The Board has also concurrently accepted the resignation of co-founder, President and Board member John Howell, effective on September 1, 2022. The Board has been reviewing CEO candidates and has appointed David Knight as interim CEO until a formal selection is made. David Knight has been appointed by the Board to replace Dan Hodges. Knight has been advising COMSovereign over the past several months. He previously served as CEO of Dispersive Holdings, a cybersecurity company based in Atlanta, GA and was CEO of Federos.

08:04 EDT Tyme Technologies merger with Syros recommended by Glass Lewis and ISS - Tyme Technologies (TYME) announced that independent proxy advisory firms GlassLewis and ISS have recommended that Tyme stockholders vote "for" the previously announced merger of Tyme and Syros Pharmaceuticals /SYRS) and "for" all other matters to be voted upon at the company's upcoming Special Meeting of Stockholders scheduled for September 15. On July 3, Syros and Tyme entered into an Agreement and Plan of Merger, pursuant to which Tyme will merge with a wholly owned subsidiary of Syros. In the merger, it is expected that Syros would issue approximately 74.3 million shares of its common stock to Tyme stockholders to acquire Tyme and Tyme stockholders are expected to receive approximately 0.4312 shares of Syros common stock for each share of Tyme common stock. Upon closing of the merger, Tyme will become a wholly owned subsidiary of Syros. Concurrent with the merger, Syros announced a $130M private investment in public equity financing at a price per unit of 94c.

08:04 EDT Perella Weinberg Partners appoints Raj Dayalan as partner - Perella Weinberg Partners announced that Raj Dayalan has joined the Firm as a Partner in its Advisory Business. Based in Los Angeles, Mr. Dayalan will work within the Firm's Technology Group and provide strategic and financial advice to clients across North America.

07:56 EDT Science 37, NuvoAir partner for respiratory clinical trials - Science 37 Holdings announced a partnership with NuvoAir, to incorporate remote collection of respiratory endpoints data into clinical trial designs-helping to bypass the need for patients to visit hospital sites for lung function testing and other respiratory assessments. NuvoAir's clinical trial solution enables the collection and integration of multiple endpoints which are captured from the comfort of patients' homes via a suite of connected devices; an integrated patient app; clinician software; and a wrap-around clinical service. This solution facilitates the deployment of agile and fully decentralized clinical trials, unlocking many of the potential benefits of agile trials, such as universal access for patients and providers, accelerated enrollment, better retention rates and increased diversity of trial enrollees.

07:47 EDT Linamar to supply commercial vehicle eAxle program to Workhorse Group - Linamar (LIMAF) announced that it has secured a new eAxle system contract with Workhorse Group (WKHS) for commercial vehicle delivery trucks. This is Linamar's first major eAxle contract with a Commercial Vehicle OEM and builds upon the previous success in the light vehicle eAxle segment. Linamar will be the Tier 1 supplier for the complete beam eAxle system. "This is an exciting new project for Linamar," said Linda Hasenfratz, Linamar's Executive Chair and CEO. "Our eLIN Group's beam eAxle product lines have been gaining attention within the Commercial Vehicle space for some time now. Our portfolio of electrified business continues to grow and expanding into diverse pathways such as Commercial Vehicles is a key element of our strategy; it is great to see the efforts of our Commercial Vehicle eAxle design and development come to fruition. We look forward to the opportunity to work with a world class organization like Workhorse Group."

07:44 EDT Cerence selected by BMW Group for AI-powered virtual assistant - Cerence (CRNC) has been selected by BMW (BMWYY) to create a new voice and AI-powered virtual assistant in the latest version of the BMW Intelligent Personal Assistant. These new capabilities are expected to be available first in the all-new BMW 7 Series and BMW i7 models. In the latest generation of BMW IPA, Cerence delivers enhanced natural language understanding that aims to makes it easier for BMW drivers and passengers to operate various in-car functions and complete tasks by using their voice. BMW IPA can now serve spoken prompts about specific functions that drivers may want to know about, maximizing their safety, productivity and comfort on the road. BMW drivers in China will also benefit from increased functionality as BMW IPA now offers voice-powered control of key WeChat features like sending a message or making a voice call.

07:42 EDT Jushi Holdings debuts cannabis-infused chocolates by Tasteology - Jushi Holdings announced the launch of cannabis-infused chocolates by Tasteology in Massachusetts. The debut of the Company's latest product line, which has been handcrafted by Jushi's Director of Manufacturing and Bravo's Top Chef: Just Desserts finalist, Matt Petersen, in concert with Jushi's product development team, marks the Company's entrance into the cannabis-infused chocolates market.

07:41 EDT PyroGenesis' zero-emission plasma torches selected by magnesium producer - PyroGenesis has been selected by a an international producer of magnesium metal to test PyroGenesis' zero-emission plasma torches as part of their process for transforming mining waste and recycled minerals into high-value metal. At this time, the name of the client remains anonymous for confidentiality reasons. First, at the request of the client, PyroGenesis has developed a method to clean and decontaminate particulate matter produced during primary magnesium production. The second initiative is to process the metal waste stream known as dross, for the purpose of recovering valuable metal. Metal recovery from dross is not widespread in the magnesium industry, due to the complexity of the process and the inherent challenges of working with magnesium. PyroGenesis has already received a small purchase order for the cleaning and decontamination initiative, with a Q4 targeted end date for the conceptual testing. The dross recovery initiative is still in the planning stages.

07:38 EDT Sabina Gold & Silver makes formal construction decision for Goose Gold mine - Sabina Gold & Silver Corp. provides an update on advancements of the Goose Mine development at the Company's 100% owned Back River Gold District in Nunavut, Canada. The Goose Mine is the Company's first mine on the 80 km long Back River Gold District, a multi-generational mining district already with a high-grade world class gold endowment. Over the past few years, Sabina has been steadily advancing logistics, civil works, engineering and procurement. All pre-development activities are now completed and we are ready for full construction to commence in 2023. All major equipment and materials required for construction have been either procured, marshalled at our east and west transportation hubs, have been delivered or are in transit to the Port Facility in Bathurst Inlet, Nunavut. In addition, the underground ramp has been progressed to our first ore access sublevel and will be sufficiently completed to enable underground drilling of the V2 zone in the 4th quarter of this year. With financing in hand and these significant activities completed, the Board of Directors of the Company has made a formal construction decision for the Goose Mine. After the Company arranged over ~C$800 million of project financing package earlier this year, significant procurement, engineering and civil work has been completed at both the Goose site and the Port facility. Of the C$610 million CAPEX estimated, approximately C$218 million was identified as direct equipment and materials purchases. Sabina has procured, or has committed agreements to procure, just over 75% of these identified purchases. Reconciliation on purchases have seen an average overall inflationary escalation of 14% since March of 2021, with a 20% escalation on the purchases made in 2022. The Company continues to monitor, with a strategy of pre-planning and accelerating procurement efforts to reduce exposure to inflationary impacts. Efforts now focus on securing the remaining 25% of materials required.

07:37 EDT Apple Store goes down ahead of iPhone event - The Apple Store has gone down ahead of a major iPhone event on Wednesday. On its website, Apple says "Be right back. We're making updates to the Apple Store. Check back soon." Apple is expected to announce a new iPhone, new Apple Watches, and new AirPods Pro. Reference Link

07:35 EDT Saia reports August LTL shipments per workday declined 1.9% - Saia is providing LTL shipment and tonnage data for the first two months of the third quarter. In July 2022, final LTL shipments per workday declined 1.1%, LTL tonnage per workday increased 2.9% and LTL weight per shipment increased 4.0% to 1,436 pounds compared to 1,381 pounds in July 2021. In August 2022, LTL shipments per workday declined 1.9%, LTL tonnage per workday increased 0.4% and LTL weight per shipment increased 2.3% to 1,431 pounds compared to 1,399 pounds in August 2021

07:34 EDT Praxis Precision Medicines provides update on pediatric epilepsy programs - Praxis Precision Medicines (PRAX) plans to start the PRAX-222 EMBRAVE clinical study for the treatment of pediatric patients with early-seizure-onset SCN2A developmental and epileptic encephalopathy - DEE -, after the FDA cleared the Investigational New Drug application for the initial dose cohort. Following collection of the safety and efficacy data from the first cohort of patients in the EMBRAVE study, the data will be evaluated and submitted to the FDA to seek authorization for further dose escalation. Praxis also intends to start the PRAX-562 Phase 2 study for the treatment of pediatric patients with SCN2A and SCN8A DEEs outside of the U.S. before the end of 2022, after the FDA placed a clinical hold on its second IND application for PRAX-562. Praxis has initiated discussions with the FDA to provide clarification about the pre-clinical and clinical data packages in relation to the clinical hold correspondence. Topline results for the PRAX-562 Phase 2 study for the treatment of pediatric patients with SCN2A and SCN8A DEEs are expected in 2023.PRAX-222 has received Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation from the FDA, and ODD from the EMA for the treatment of SCN2A-DEE. The PRAX-222 program is ongoing under a collaboration with Ionis Pharmaceutics (IONS) and RogCon.

07:34 EDT Tradeweb Markets reports total trading volume for August of $23.4T - Tradeweb Markets reported total trading volume for August of $23.4T. Average daily volume for the month was $1.02T, an increase of 13% year-over-year.

07:33 EDT Eastern Bankshares announces new $200M share repurchase plan - Eastern Bankshares announced that it has received regulatory non-objection to proceed with a new share repurchase program, under which the company is authorized to purchase up to 8,900,000 shares, representing approximately 5% of Eastern's shares of common stock now outstanding. The repurchase program, which is limited to $200M through August 31, 2023, may be modified or terminated by the board of directors of the company at any time.

07:32 EDT Victoria Gold provides update on exploration drill program - Victoria Gold is pleased to provide an update on its exploration drill program. The Eagle exploration drilling program took place from December 2021 through May 2022 and continued on the success of the 2021 Eagle Deep drilling program. The 2022 program focused on key areas for the potential expansion of the Eagle Gold deposit to the west of the existing Eagle Gold pit. In total, 10,342 meters of diamond drilling in 23 drill holes have added approximately 500m of mineralized strike length from the current Eagle pit boundary. Highlights of the Eagle exploration program include: DG22-106c: 301.0m @ 0.52 g/t Au from 102.0M including: 69.5m @ 0.72 g/t Au from 244.0m; DG22-1013C: 215.0m @ 0.60 g/t Au from 206.5m including 51.0m @ 0.88 g/t Au from 355.5m; DG22-1017C: 72.3m @ 1.14 g/t Au from Surface including: 32.7m @ 2.24 g/t Au from 50.3m; DG22-1023C: 240.3m @ 0.63 g/t Au from 254.0M including: 78.0m @ 1.29 g/t Au from 284.0m. "Last year's exploration drilling clearly demonstrated there is more to the Eagle deposit than was captured in the 2019 Technical Report." commented John McConnell, President and CEO of Victoria. "Of particular note from the 2022 campaign, is how a small, focused drilling program delineated mineralization extensions to the Eagle deposit. This year's drilling results will be included in an updated Eagle Gold Mineral Resource in Q1 2023."

07:27 EDT Paycor announces pricing of offering of common stock - Paycor HCM announced the pricing of an underwritten public offering of 5,000,000 shares of common stock on behalf of investment funds advised by Apax Partners LLP at a price to the public of $27.35 per share. The offering consists of 3,531,941 shares offered by Pride Feeder, L.P. and 1,468,059 shares offered by AIX Pride Syndication, L.P., respectively. Each of the selling stockholders are controlled by investment funds advised by Apax Partners LLP. Paycor will not receive any of the proceeds from the sale of the shares being offered by the selling stockholders but will bear the costs associated with the sale of such shares, other than any underwriting discounts and commissions. The offering is expected to close on September 9, 2022, subject to customary closing conditions. Goldman Sachs & Co. LLC is acting as underwriter for the offering.

07:24 EDT Manitou Gold provides exploration results for Western Nickel spin-out - Manitou Gold provides interim results from its ongoing exploration activities, in support of the initiative to spin out nickel-cobalt-PGE commodities from the Goudreau project into a newly incorporated subsidiary, Western Nickel Corp. Highlights: Over 30 additional nickel bearing ultramafic bodies interpreted from geophysics. 100% success rate in ground truthing ten ultramafic hosted nickel-cobalt targets exposed at surface. Grab samples from seven targets returned up to 0.31% nickel, 350 ppm cobalt, 1.84 g/t palladium and 0.24 g/t platinum; results from the remaining three targets are pending. Drill program underway with two out of three drill holes completed. The first two holes drilled 500 m and 900 m west of discovery hole MTU-22-14 intersected continuously serpentinized and mineralized intervals of ultramafic rocks over a core length in excess of 200 metres. Third drill hole to test the strongest portion of the magnetic anomaly to the north of discovery hole MTU-22-14 with 48 m @ 0.25% Nickel is currently underway. Microprobe analysis of core samples from discovery hole MTU-22-14 indicates that nickel is dominantly hosted in heazlewoodite and lesser nickel alloys. No nickel was detected in silicate phases of the rock indicating near total liberation of silicate nickel. Diamond drilling is currently underway at the Company's 100% owned Goudreau project, following up on the recent results that demonstrate the untested potential for significant nickel mineralization comparable to Canada Nickel's Crawford deposit, located in Timmins, and the Dumont nickel deposit, located in Quebec. As reported on June 13, 2022, Manitou intersected a 48 m wide interval of highly serpentinized ultramafic rocks grading 0.25% Ni and 100 ppm Co starting at 29 m after reaching bedrock. The hole was collared in nickel mineralization near the southern margin of the ultramafic intrusion and, therefore, did not intersect the full width of the mineralized zone. To date, the Company has completed two drill holes located 500 and 900 metres west of discovery hole MTU-22-14, in a separate intrusion that measures more than 800 metres long and approximately 200-300 metres wide.

07:20 EDT Xos names W.W. Williams as pilot service provider in Arizona - Xos has named W.W. Williams as a pilot service provider in the state of Arizona. W.W. Williams is a services provider that offers mechanical service and repair, power generation, and warehousing and logistics services. As part of the agreement, W.W. Williams will provide maintenance service and repairs on Xos vehicles in regions of Phoenix, Ariz. and Tucson, Ariz. W.W. Williams will also support Xos customers with an inventory of in-stock Xos service parts.

07:19 EDT XPO Logistics appoints Jamie Harris as CFO for RXO spin-off - XPO Logistics announced that JamieHarris will become CFO of RXO, the planned spin-off of XPO's brokered transportation platform. Harris will join XPO as CFO of the North American transportation division, effective September 26 and will lead RXO's finance operations when the separation is complete. He will report to Drew Wilkerson, who, as previously announced, will be CEO of RXO, and currently serves as president, transportation - North America. Harris joins XPO from global manufacturer SPX Technologies, where he served as CFO and treasurer. Prior to SPX, Harris was CFO and interim CEO with Elevate Textiles and CFO with Coca-Cola Consolidated. XPO intends to spin off its asset-light brokered transportation platform from its asset-based less-than-truckload business, creating two separate, publicly traded companies with vast growth prospects in North America. XPO expects to complete the spin-off in 4Q22.

07:18 EDT Axsome Therapeutics announces publication of post-hoc analysis of Sunosi - Axsome Therapeutics announced the publication of a post-hoc analysis comparing the effects of Sunosion excessive daytime sleepiness in patients with and without a history of depression. Sunosi is the first and only dual-acting dopamine and norepinephrine reuptake inhibitor indicated to improve wakefulness in adult patients with excessive daytime sleepiness due to narcolepsy or obstructive sleep apnea. This secondary analysis included data from two 12-week, randomized, double-blind, placebo-controlled trials in adult patients with EDS associated with narcolepsy or OSA. The analysis showed that treatment with Sunosi improved EDS symptoms both in patients with and without a clinical history of depression, compared to placebo. The results also confirmed earlier findings of a high prevalence of a history of depression in participants with narcolepsy or OSA, and suggest that increased awareness of this association may have clinical significance. Common treatment-emergent adverse events were also similar in those with and without a history of depression.

07:16 EDT Toyota announces GR Supra Manual Transmission now on sale - The 2023 Toyota GR Supra: The Manual Transmission is available as an option on the Supra 3.0 and 3.0 Premium. The GR Supra MT is arriving on dealer lots now with a Manufacturer's Suggested Retail Pricing starting at $52,500. "When we revealed the GR Supra back in 2019, we tapped into a heritage nameplate for Toyota," said Mike Tripp, vice president of Toyota Vehicle Marketing and Communications. "But we were regularly asked if there would be a manual version. We immediately took that feedback to heart and started developing it, and we're happy that we can now bring customers the perfect complement for Supra's high-torque, high output engine with a six-speed manual."

07:15 EDT Solaris Resources reports assay results from Warintza Project - Solaris Resources is pleased to report assay results from a series of holes aimed at growing the Northeast Extension of the 'Indicative Starter Pit' at its Warintza Project in southeastern Ecuador. Highlights are listed below, with a corresponding image in Figure 1 and detailed results in Tables 1-2. Highlights Additional drilling has expanded the Northeast Extension of the 'Indicative Starter Pit' recently estimated at 180 Mt at 0.82% CuEq (Indicated) and 107 Mt at 0.73% CuEq within the Warintza Mineral Resource Estimate . This zone is characterized by near surface, high-grade mineralization and remains open for further growth with follow-up drilling underway. SLS-66 was collared on a platform at the northeastern limit of the Warintza Central grid and drilled southwest into an open volume, returning 124m of 0.82% CuEq within a broader interval of 622m of 0.42% CuEq starting from surface SLS-66 follows from previous holes SLS-63 and SLS-54, which were drilled from the same pad to the north and southeast and respectively returned high-grade intervals of 230m of 1.02% CuEq and 356m of 0.73% CuEq within broader intervals; SLS-64 was collared on a platform at the northern limit of Warintza Central and drilled north-northeast into an open volume, returning 110m of 0.54% CuEq from near surface within a broader interval of 440m of 0.48% CuEq, extending and broadening the zone to the north in this area SLS-64 follows from previous holes SLS-62 and SLS-48, which were drilled from the same pad to the northeast and south and respectively returned high-grade intervals of 168m of 0.68% CuEq and 100m of 1.64% CuEq within broader intervals SLS-65, which is a step out hole from a new platform 200m to the north, has now been completed after operational delays with adjustments to the platform for drilling and assays are expected within the next four weeks Mr. Jorge Fierro, Vice President, Exploration, commented: "Drilling from existing and recently-completed platforms in the Northeast Extension zone is a key driver in the expansion of the 'Indicative Starter Pit', and we look forward to reporting the next set of results in the near future as the backlog of assays pending is now resolved."

07:14 EDT 5E Advanced Metals enters research collaboration with Boston College - 5E Advanced Materials announced its research collaboration agreement with Boston College for the advancement of boron-based materials research in solar energy systems. Under the terms of the agreement, 5E will provide funds to and collaborate with Boston College in exploring and developing novel boron-based materials that have the potential to integrate solar energy capture, conversion, and storage into a single closed system. This research has the potential to create intellectual property and commercialization pathways for 5E as it pertains to the manufacturing of boron enhanced solar energy systems.

07:13 EDT Veeva Systems announce INCOG BioPharma implemented its Vault Quality Suite - Veeva Systems announced that INCOG BioPharma Services implemented Veeva Vault Quality Suite as a foundation for digital excellence across its new 90,000-square-foot manufacturing facility. Vault Quality empowers INCOG BioPharma's teams with a connected digital system that simplifies working with partners and provides transparency to customers. "Launching our facility with modern quality solutions that can keep up with strict project requirements while streamlining collaboration was a top priority," said JR Humbert, vice president of quality, INCOG BioPharma. "Veeva Vault Quality Suite helps us deliver real-time visibility to clients, increasing operational efficiency, GxP compliance, and trust." A contract development and manufacturing organization, CDMO, specializing in sterile injectable fill-finish, INCOG BioPharma is unifying quality functions on a single platform to speed manufacturing and delivery and maintain high levels of quality and compliance. The company uses Veeva Vault QMS to accelerate quality processes using built-in best practices, Veeva Vault QualityDocs to streamline document management and automate workflows, and Veeva Vault Training to develop curricula that ensure job qualifications.

07:13 EDT Glaukos announces two iDose TR trials met primary endpoints - Glaukos announced topline data for both Phase 3 pivotal trials of iDose TR that successfully achieved its pre-specified primary efficacy endpoints through three months in both Phase 3 trials and demonstrated excellent tolerability and a favorable safety profile through 12 months. For each of the two Phase 3 iDose TR pivotal trials, GC-010 and GC-012, both the fast- and slow-release iDose TR arms achieved the pre-specified primary efficacy endpoint of non-inferiority to the active comparator arm through three months. For the GC-010 trial, the intraocular pressure, or IOP, reductions from baseline over the first three months were 6.6-8.5 mmHg in the slow-release iDose TR arm, versus 6.6-7.7 mmHg in the timolol control arm. For the GC-012 trial, IOP reductions from baseline over the first three months were 6.7-8.4 mmHg in slow-release iDose TR arm, versus 6.8-7.2 mmHg in the timolol control arm. Overall, 93% of slow-release iDose TR subjects remained well-controlled on the same or fewer IOP-lowering topical medications at 12 months compared to screening after a single administration of iDose TR, versus 67% of timolol control subjects in both Phase 3 trials. Additionally, 81% of slow-release iDose TR subjects were completely free of IOP-lowering topical medications at 12 months across both trials. iDose TR demonstrated excellent tolerability with 98% of slow-release iDose TR subjects continuing in the trial at 12 months, versus 95% of timolol control subjects across both Phase 3 trials. iDose TR demonstrated a favorable safety profile through 12 months, with no adverse events of corneal endothelial cell loss, no serious corneal adverse events and no adverse events of periorbital fat atrophy. Notably, conjunctival hyperemia occurred at a very low rate of 3% for slow-release iDose TR subjects. The most frequent adverse event for slow-release iDose TR subjects was mild transient iritis at a rate of 6% in both Phase 3 trials. In-office administration of iDose TR was successfully employed with various subjects across multiple sites with outcomes that were consistent with the Phase 3 trials, thus demonstrating the feasibility of iDose TR administration in the office setting. Based on the combined efficacy and safety results from both Phase 3 pivotal trials, Glaukos plans to move forward with its plans for an NDA submission to the FDA for the slow-release iDose TR model, with an expected FDA review and decision completed by the end of 2023. Administered during a micro-invasive procedure, the iDose TR contains a novel formulation of travoprost, a prostaglandin analog used to reduce IOP. Once all travoprost is released, the iDose TR was designed to be removed and replaced with a new iDose TR, thus potentially offering an alternative to daily eye drop treatment. The iDose TR Phase 3 clinical program consists of two prospective, randomized, double-masked pivotal clinical trials designed to compare the safety and efficacy of a single administration of one of two iDose TR models with different travoprost release rates to topical timolol ophthalmic solution, 0.5% BID, in reducing elevated IOP in subjects with open-angle glaucoma, or OAG, or ocular hypertension. The two iDose TR pivotal trials are nearly identical in terms of design, protocol, predefined endpoints, size and randomization. The first of the two Phase 3 pivotal trials, referred to as GC-010, randomized a total of 590 subjects, comprised of 200 subjects in the slow-release iDose TR arm, 197 subjects in the fast-release iDose TR arm and 193 subjects in the timolol active comparator arm. The second of the two Phase 3 pivotal trials, referred to as GC-012, randomized a total of 560 subjects, comprised of 183 subjects in the slow-release iDose TR arm, 185 subjects in the fast-release iDose TR arm and 193 subjects in the timolol active comparator arm. In total, the Phase 3 trials randomized a total of 1,150 subjects across 89 clinical sites. The primary efficacy endpoint of the Phase 3 studies was a non-inferiority comparison to topical timolol 0.5% BID over the first 3 months, defined as time-matched diurnal IOP measurements at 8 a.m. and 10 a.m. at Day 10, Week 6 and Month 3. Primary safety evaluations were performed through 12 months. Mean baseline IOP was approximately 24 mmHg across each arm in each study. Approximately 81% of slow-release iDose TR subjects had OAG while the remaining 19% had ocular hypertension. Approximately 67% of slow-release iDose TR subjects were on one or more IOP-lowering medications at screening, including 23% of subjects who were on two or more IOP-lowering medications at screening.

07:12 EDT OTC Markets Group welcomes Pantheon Resources to OTCQX - OTC Markets Group announced Pantheon Resources, an oil and gas company with a 100% working interest in all of its projects spanning approximately 153,000 acres adjacent and near to transportation and pipeline infrastructure on the Alaska North Slope, has qualified to trade on the OTCQX Best Market. Pantheon Resources Plc upgraded to OTCQX from the Pink market.

07:10 EDT First Wave BioPharma provides update on adrulipase clinical progam - First Wave BioPharma announced the selection of an enhanced enteric microgranule drug delivery formulation for the ongoing development of its adrulipase clinical program. First Wave BioPharma now plans to submit an Investigational New Drug amendment to the FDA for a Phase 2 "proof-of-concept" clinical study investigating the optimized version of adrulipase as a treatment for exocrine pancreatic insufficiency associated with cystic fibrosis and chronic pancreatitis. First Wave BioPharma expects to initiate the Phase 2 trial prior to year-end 2022 following acceptance of the IND. In vitro data suggest the new formulation provides a delayed-release profile that should ensure adrulipase is protected in the stomach and delivered to the targeted areas of the GI tract, allowing for adrulipase to mix with food in the duodenum where it can then provide its therapeutic effect. Additionally, the research indicates the enhanced formulation has the potential to significantly decrease the number of pills a patient would need to take to achieve the desired therapeutic effect. Further, First Wave BioPharma has identified manufacturing improvements that have the potential to lower the cost of goods by significantly increasing production yields.

07:09 EDT Casi, BioInvent announce first-patient dosing in Phase 1 study of BI-1206 - CASI Pharmaceuticals and BioInvent International announced the first-patient-in in China Phase 1 dose-escalation and expansion study of BI-1206, a first-in-class fully human monoclonal antibody that targets FcgammaRIIB, in combination with rituximab in patients with relapsed/refractory Non-Hodgkin's Lymphoma, NHL. The study design is to assess the safety, tolerability, pharmacology, and clinical activity of BI-1206. The patient was enrolled at Henan Cancer Hospital. Wei-Wu He, Ph.D., CASI's Chairman, and Chief Executive Officer, commented, "We are excited to dose the first patient in the continued evaluation of BI-1206. BI-1206 has previously shown encouraging early signs of efficacy in Phase 1, a tolerable safety profile, and the potential to be used with multiple therapeutic mAbs that rely on ADCC/CDC* for efficacy. This Phase 1 trial in China will generate valuable information and has the potential to provide early evidence of clinical activity in the treatment of relapsed or refractory Non-Hodgkin's Lymphoma."

07:08 EDT 2seventy to initiate KarMMa-9 study to evaluate Abecma - 2seventy Bio (TSVT) announced plans to initiate the KarMMa-9 study to evaluate Abecma in newly diagnosed multiple myeloma patients who have suboptimal response to transplant. The company, in partnership with Bristol Myers Squibb (BMY), plans to provide additional information about the design and timing of the study at the earliest upcoming opportunity.

07:07 EDT PharmaTher announces completion of IND-enabling study for KETARX patch - PharmaTher Holdings announced that it has completed an IND-enabling pharmacokinetic and tolerability study of KETARX Ketamine Patch in minipigs. The KETARX Ketamine Patch was manufactured by its CDMO partner, LTS LOHMANN Therapie-Systeme AG. The Study was completed at Aurigon Toxicological Research Center, under full Good Laboratory Practice compliance, which is a prerequisite for upcoming phase 2 clinical studies according to FDA guidelines. PharmaTher is developing KETARX Ketamine Patch to improve the administration burden in support of current ketamine use and as a potential therapeutic alternative in the treatment of various mental health, neurological and pain disorders.This Study aimed to investigate the plasma concentration and pharmacokinetics of ketamine after administration of KETARX Ketamine Patches to female Gottingen Minipigs. The degree of local tolerance was examined as reflected by erythema, edema formation and other effects after removal of the pressure dressing. To determine the concentration of ketamine in the blood plasma, samples were collected up to 4 days after the administration. The plasma concentrations of ketamine were measured and the pharmacokinetic evaluation was performed at the Analytical Department of ATRC. The delivery of ketamine through intramuscular injection results in rapid delivery of a bolus dose of ketamine. To alter the speed and availability of ketamine, the use of intravenous infusion is the standard strategy; however, it requires complex equipment and technical expertise to administer. The Study demonstrated that KETARX Ketamine Patch applied directly to the skin was well tolerated and capable of delivering a ketamine dose over an extended period of time without modification of ketamine or additional formulation enhancement. Pharmacokinetic evaluation of intradermal administration of ketamine via KETARX Ketamine Patch demonstrated extended delivery of ketamine over 40 hours with a slow and elongated increase of plasma levels over 18 hours and a slow decline for an additional 24 hours in a linearly proportional manner relative to dose. Overall, the small patch size used in this Study supports the opportunity to increase dose through increased size, drug load or concentration of ketamine and will allow increases in ketamine dosing to better align with intramuscular and intravenous administration. No clinical symptoms, mortality or body weight differences were observed throughout the study. Local tolerance and histopathology assessment of the patch without ketamine demonstrated that it is well tolerated and with ketamine, the patch showed only a minor difference compared to control.

07:06 EDT Seres Therapeutics completes rolling submission for SER-109 BLA to FDA - Seres Therapeutics announced it has completed the rolling submission process for its biologics license application, or BLA, to the FDA for SER-109 for the prevention of recurrent C. difficile infection, or rCDI. SER-109 is an entirely new treatment modality that shows promise to improve the current standard of care for rCDI.

07:05 EDT Priority Technology appoints Tim O'Leary as CFO - Priority Technology announced the appointment of Tim O'Leary to the position of CFO. O'Leary replaces Mike Vollkommer, who will retire on September 16.

07:04 EDT Old Dominion says August LTL revenue per day increased 14.5% vs. last year - Old Dominion Freight Line reported certain less-than-truckload "LTL" operating metrics for August 2022. Revenue per day increased 14.5% as compared to August 2021 due to an increase in LTL revenue per hundredweight that was slightly offset by a 0.9% decrease in LTL tons per day. The change in LTL tons per day was attributable to a 2.7% decrease in LTL shipments per day that was partially offset by a 1.8% increase in LTL weight per shipment. For the quarter-to-date period, LTL revenue per hundredweight and LTL revenue per hundredweight, excluding fuel surcharges, increased 18.1% and 7.3%, respectively, as compared to the same period last year. Greg C. Gantt, President and Chief Executive Officer of Old Dominion, commented, "Old Dominion produced solid revenue growth for the first two months of the third quarter. While our volumes decreased on a year-over-year basis, we continued to improve our yield through the consistent execution of our yield management initiatives. Providing shippers with superior service is required to support these initiatives, and our service levels remain best-in-class. We remain focused on delivering superior service at a fair price and believe customer demand for our value proposition remains strong, which positions us to win further market share."

07:03 EDT Roche to acquire Good Therapeutics for $250M upfront - Good Therapeutics announced it has entered into a definitive merger agreement to be acquired by Roche. With this acquisition, Roche will gain rights to Good Therapeutics' innovative, conditionally active, PD-1-regulated IL-2 program and an exclusive right to the platform technology for the development of PD-1-regulated IL-2 receptor agonist therapeutics. Under the terms of the merger agreement, Roche will make an upfront cash payment of $250M for the shares on a fully diluted basis and additional payments based on the achievement of predetermined development, regulatory, and commercial milestones. The transaction is conditioned upon clearance under the Hart-Scott-Rodino Antitrust Improvements Act and is expected to close in the third quarter of 2022. Following the close of the Roche acquisition, the Good Therapeutics team plans to apply the technology for the design of conditionally active therapeutics to other targets in immuno-oncology and beyond in a new company, Bonum Therapeutics.

06:57 EDT Sonic Automotive opens EchoPark Retail Hub in Sacramento, California - Sonic Automotive announced the continued expansion of the EchoPark Automotive brand with the opening of its newest Retail Hub in Roseville near Sacramento, California. EchoPark Sacramento is the brand's second location in California. To date, EchoPark has 41 Retail Hubs and Delivery Centers across 21 states, and is continuing its expansion toward a nationwide distribution network that is expected to reach 90 percent of the U.S. population by 2025.

06:54 EDT Traeger promotes Jim Hardy to COO, Cole VandenAkker to Chief Sales Officer - Traeger announced two executive promotions. Jim Hardy has been promoted to COO and Cole VandenAkker has been promoted to Chief Sales Officer. Jim Hardy has served as Chief Supply Chain Officer of Traeger since March 2021. He previously served as Chief Operating Officer of Fanatics, Inc. and Executive Vice President Global Operations of Under Armour. Cole VandenAkker has served as Traeger's Executive Vice President of Global Sales since May 2020 and oversaw all National Sales prior to that appointment.

06:52 EDT Hartford Financial president Doug Elliot to retire - Hartford announced Doug Elliot will retire as the company's president effective Dec. 31, following more than 11 years with the company. Effective Nov. 1, Hartford will realign its leadership structure in preparation for Elliot's retirement. A. Morris Tooker, who currently heads Middle & Large Commercial, will report directly to CEO Christopher Swift and will take on expanded responsibility for Global Specialty and Sales & Distribution. Stephanie Bush will report directly to Swift and maintain her role as head of Small Commercial and Personal Lines. The company's Global Chief Underwriting Officer, Ross Fisher, also will report directly to Swift and will continue to have responsibility for underwriting across the enterprise, Global Reinsurance, Risk Engineering and the company's Internet of Things operations.

06:50 EDT Pfizer's Streptococcus vaccine candidate given Breakthrough Therapy Designation - Pfizer's investigational Group B Streptococcus vaccine candidate, GBS6 or PF-06760805, received Breakthrough Therapy Designation from the FDA for the prevention of invasive GBS disease due to the vaccine serotypes in newborns and young infants by active immunization of their mothers during pregnancy. The FDA decision is informed by the interim analysis of a placebo-controlled Phase 2 study evaluating the safety and immunogenicity of GBS6 in healthy pregnant women aged 18 to 40 years, who were vaccinated during the second or early third trimester of pregnancy. The study remains ongoing, and Pfizer will publish outcomes from this clinical trial when it is completed. This decision follows the FDA's March 2017 decision to grant Fast Track status to GBS6.

06:45 EDT RF Industries receives $3.5M in follow-on orders - RF Industries announced it has received $3.5M of follow-on orders from its newest North American Tier 1 wireless carrier customer at the Company's Cables Unlimited division for its OptiFlex hybrid fiber solution.

06:43 EDT eGain announces pre-built connector for IBM Watson Assistant - eGain (EGAN) announced the availability of a pre-built connector for IBM (IBM) Watson Assistant. The connector leverages eGain's BYOB - Bring Your Own Bot - architecture, allowing business users to easily plug in the Watson Assistant into the eGain platform with no coding. The eGain Connector for Watson Assistant aims to improve customer, agent, and business experiences.

06:42 EDT Agora CEO intends to purchase $30M of ADSs or Class A ordinary shares - Agora announced that Mr. Tony Zhao, founder, chairman and CEO of Agora, has informed Agora's board of directors of his intention to use his personal funds to purchase up to an aggregate of $30M of Agora's ADSs or Class A ordinary shares for the next 12 months, pursuant and subject to relevant rules and regulations and Agora's insider trading policy. As previously announced, Agora's board of directors had authorized a share repurchase program, under which Agora may repurchase up to an aggregate of $200M of its Class A ordinary shares in the form of ADSs, which is effective until the end of February 2023. As of June 30, 2022, Agora had repurchased $19.8M of its ADSs under the share repurchase program and is still authorized to use the remaining quota for repurchases within the term of the plan.

06:40 EDT Arizona Sonoran Copper releases assay from drilling at Parks/Salyer - Arizona Sonoran Copper Company releases assays from 9 drill holes from the 14-hole expanded exploration program at Parks/Salyer, located ~1.3 mi southwest of the Company's Cactus Mine Project. Drilling extended mineralization east by up to 1,000 ft onto the Bronco Creek land, a part of the P/S Project which was acquired earlier this year. Assays are pending on 4 holes. The Company is also extending its current ionic leach sampling survey northeast of P/S, as well as eastward onto the BCE land. Highlights: Two active drill rigs, a third rig to begin drilling metallurgical holes late September; Maiden mineral resource on P/S in Q4 2022: ECP-084: 531.4 ft @ 1.10% TCu, 0.98% Cu TSol, 0.012% Mo Incl. 247.0 ft @ 1.45% TCu, 1.35% Cu TSol, 0.014% Mo And 354.0 ft @ 0.65% TCu, 0.018% Mo; ECP-086: 224.0 ft @ 2.24% TCu, 2.19% Cu TSol, 0.010% Mo Incl. 114.0 ft @ 2.63% TCu, 2.60% Cu TSol, 0.011% Mo; ECP-090: 474.0 ft @ 0.82% TCu, 0.73% Cu TSol, 0.007% Mo And 482.0 ft @ 0.42% TCu, 0.011% Mo; ECP-092: 216.8 ft @ 1.41% TCu, 1.35% Cu TSol, 0.005% Mo; Incl. 97.0 ft @ 2.29% TCu, 2.20% Cu TSol, 0.004% Mo. George Ogilvie, Arizona Sonoran President and CEO commented, "These results continue to demonstrate the potential of Parks/Salyer to underpin and augment the multi-billion-pound Cactus copper project located only 1.3 miles (2 km) to the northeast. These drill holes extend mineralization from the eastern Parks/Salyer border onto the new Bronco Creek land by upwards of 1,000 ft. With drill spacing now at 500 ft (150 m) centres, we have defined the general eastern horst block extent, with assays pending on the west side for 4 holes. The team has now moved on to a 250 ft infill drilling program to increase the confidence of the mineralization to an indicated resource category. Our goal is to issue a maiden inferred mineral resource estimate on Park/Salyer within Q4 2022."

06:36 EDT Nextdoor, Vote.org partner to encourage midterm election voting - Nextdoor announced a strategic partnership with Vote.org. For the third consecutive election cycle, Nextdoor is working with Vote.org to use technology to simplify political engagement, increase voter turnout, and strengthen American democracy for neighbors.

06:34 EDT Walmart and UnitedHealth launch 10-year collaboration - Walmart (WMT) and UnitedHealth (UNH) announced the beginning of an initial 10-year, wide-ranging collaboration. The collaboration will start in 2023 with 15 Walmart Health locations in Florida and Georgia and expand into new geographies over time. Optum, a UnitedHealth Group business, will help enable Walmart Health clinicians through analytics and decision support tools to deliver comprehensive value-based care for seniors and Medicare beneficiaries. These capabilities will enhance the care already provided at Walmart Health centers. Beginning in January 2023, the collaboration will include a co-branded Medicare Advantage plan in Georgia, UnitedHealthcare Medicare Advantage Walmart Flex. Also in January 2023, Walmart Health Virtual Care will be in network for commercial members in UnitedHealthcare's Choice Plus PPO plan, giving consumers another option to access care when and where they want it. Eventually, the collaboration aims to serve more people, including those across commercial and Medicaid plans, by providing access to fresh food and enhancing current initiatives to address social determinants of health, over-the-counter and prescription medications, and dental and vision services.

06:33 EDT ViewRay announces China NMPA approval for MRIdian Therapy System - ViewRay announced that the company's MRIdian MRI-Guided Radiation Therapy System has received approval from the Chinese regulatory authority National Medical Products Administration, or NMPA, allowing for its sale and utilization throughout China. This approval expands MRIdian's global reach and offers cancer patients a new radiation therapy option, MRIdian Stereotactic MRI-Guided Adaptive Radiotherapy, or SMART, allowing treatment that integrates diagnostic-quality MR imaging, on-table adaptive replanning, and continuous, real-time, soft tissue tracking and automated beam gating.

06:29 EDT Calibre Mining reports additional drill results from Panteon North zone - Calibre Mining is pleased to report additional high-grade drill results from its Panteon North zone within the Limon Mine Complex, part of the Company's 85,000 metre resource expansion and discovery drilling program. High-grade mineralization now extends across a strike length of nearly 400 metres with consistent, plus 15 gram per tonne drill intercepts over broad, minable widths. Given a recent VTEM survey, click here for details, which has identified two, parallel five km potential mineralized corridors, the strong correlation to the high/low resistivity contact demonstrated in the recent drilling and historical mining zones Calibre has four rigs testing along strike and down plunge expansion potential. Additional High Grade Drill Result Highlights from Panteon North 52.59 g/t Au over 3.8 metres Estimated True Width, including 94.70 g/t Au over 1.1 metres; and 10.28 g/t Au over 2.1 metres ETW, including 16.50 g/t Au over 1.7 metres in Hole LIM-22-4662; 43.09 g/t Au over 3.3 metres ETW, including 155.10 g/t Au over 0.9 metres in Hole LIM-22-4647; 35.18 g/t Au over 2.8 metres ETW, including 58.00 g/t Au over 1.5 metres in Hole LIM-22-4653; 26.02 g/t Au over 8.1 metres ETW, including 41.30 g/t Au over 4.6 metres in Hole LIM-22-4665; 18.49 g/t Au over 1.1 metres ETW, including 49.30 g/t Au over 0.4 metres in Hole LIM-22-4654; 13.14 g/t Au over 3.1 metres ETW, including 49.10 g/t Au over 0.4 metres in Hole LIM-22-4651. Tom Gallo, Senior Vice President, Growth at Calibre, stated: "This is a paradigm shifting discovery for us with consistent high-grade mineralization demonstrated over considerable strike length coupled with VTEM giving strong indications there is potential to expand and discover additional zones. Drilling is underway to extend this mineralized zone to depth with visual indicators having shown positive signs. Given the grade, we expect a substantial, positive impact made to our mineral resource statement."

06:26 EDT Digihost mines 67.97 bitcoin in August - Digihost Technology provides unaudited comparative BTC production results for the month ended August 31, 2022, combined with an operations update. Production Highlights for August 2022: Mined 67.97 BTC, resulting in total holdings of 176.61 BTC at the end of August valued at approximately $3.54 million based on a BTC price of $20,050 as of August 31, 2022. Ethereum holdings of 1,000.89 ETH at the end of August valued at approximately $1.56 million based on an ETH price of $1,554 as of August 31, 2022. Total digital asset inventory value, consisting of BTC and ETH, of approximately $5.10 million as of August 31, 2022. To avoid equity dilution for its shareholders, management sold a portion of its BTC production during August to fund its energy costs. The Company remains debt free as of August 31, 2022. In continuing its support of the power needs of the local community, the Company reduced its overall energy consumption during the month of August 2022 with its operation running predominantly at off-peak hours.

06:23 EDT Aslan Pharmaceuticals presents positive data on eblasakimab at EADV Congress - Aslan Pharmaceuticals announced the presentation of new eblasakimab data at the 2022 European Academy of Dermatology and Venereology - EADV - annual congress in Milan. Three posters are being presented from September 7 to 10. The posters include previously unpublished data on biomarkers and quality-of-life measures, and new, additional analyses of clinical data from the previously reported Phase 1 multiple-ascending dose study of eblasakimab in moderate-to-severe atopic dermatitis, or AD. The data observed significant improvements in itch and sleep loss within the 8-week study period, suggesting the potential for a greater magnitude of effect with prolonged treatment, and Aslan is investigating this in the ongoing phase 2b study. Eblasakimab, a monoclonal antibody targeting IL-13Ralpha1, reduces serum biomarkers that are associated with atopy and correlated with disease severity, in patients with moderate-to-severe atopic dermatitis. Eblasakimab treatment reduced circulating levels of TARC/CCL17, IgE, and LDH, associated with disease severity in AD. Eblasakimab improves itch and sleep loss in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study. At week 8, patients in the 600mg dose group showed a 48% improvement in worst itch, versus a 13% improvement in the placebo group. 56% of patients in the 600mg eblasakimab group demonstrated at least a two point mean improvement in sleep loss, a clinically significant improvement in sleep loss, versus 15% in the placebo group. Eblasakimab improves multiple disease measures in adult patients with moderate-to-severe atopic dermatitis in a randomized, double-blinded, placebo-controlled, Phase 1 study. The poster highlights improvements in disease measures after treatment with eblasakimab.

06:19 EDT Navitas Semiconductor announces GaNSense half-bridge power ICs - Navitas Semiconductor announced the industry's first GaNSense half-bridge power ICs. These half-bridge ICs enable a new level of MHz switching frequencies while dramatically reducing the system cost and complexity compared to existing discrete solutions.

06:15 EDT BAE Systems to launch first multi-sensor satellite cluster in 2024 - BAE Systems is set to launch its first multi-sensor satellite cluster into low Earth orbit in 2024 to deliver high-quality information and intelligence in real time from space to military customers. Known as Azalea, the group of satellites will use a range of sensors to collect visual, radar and radio frequency data, which will be analysed by on board machine learning on edge processors to deliver the resulting intelligence securely, anywhere in the world while still in orbit. Following the acquisition of In-Space Missions last year, BAE Systems is one of a small number of British companies with the capability to design, build, launch and operate satellites. The expertise brought by In-Space Missions complements the Company's existing advanced technologies and will become an integral part of its multi-domain capability. Azalea will also boost the UK's ability to understand the threats and hazards in, from and through space.

06:13 EDT Quanergy's 3D LiDAR solutions integrated with Hanwha Techwin's Wisenet WAVE VMS - Quanergy Systems announced that the company is integrating it's M-Series LiDARs and QORTEX DTC 3D perception software with Hanwha's Techwin's video management software, Wisenet WAVE VMS. This will enable Hanwha customers to optimize and automate security business operations with real-time 3D data including location, direction, speed and type of objects. With Quanergy 3D LiDAR solutions integrated into Wisenet WAVE VMS, Hanwha customers will have access to advanced sensing capabilities to extend the coverage, dramatically reduce false alarms rates and reduce the operational cost of physical security deployments. The 3D volumetric sensing provided by Quanergy's solutions will enable Hanwha customers to visualize spaces with depth perception and provide extremely accurate object tracking of alarm events. This means countless event-to-action outcomes can be configured and visualized for automation, security or business intelligence.

06:11 EDT Clean Energy supplies fuel for inaugural bunkering of maritime LNG-powered ship - Clean Energy Fuels supplied fuel for the first bunkering with liquified natural gas of Pasha Hawaii's new container ship MV George III. This was the first LNG bunkering of a container ship on the U.S. West Coast. Clean Energy worked with World Fuel Services and West Coast Clean Fuels to supply the ship with over 300,000 gallons of the clean fuel. Pasha Hawaii's MV George III, a 774-foot container ship operating between Long Beach, CA, Honolulu, HI, and Oakland, CA, is the first of three LNG-powered ships that the domestic shipping company is putting into service. The three ships are expected to consume 105 million gallons of LNG fuel over the next five years.

06:10 EDT Stevanato Group and Gerresheimer AG partner for ready-to-use vial platform - Stevanato Group and Gerresheimer AG, a global provider of healthcare & beauty and drug delivery systems for pharma, biotech and cosmetics, have jointly developed a high-end Ready-To-Use solution platform with an initial focus on vials, based on Stevanato Group's EZ-fill technology. Gerresheimer AG and Stevanato Group are addressing rising demand for RTU vials in the market. A hallmark of the new RTU platform is a significant reduction in particles, improving the overall quality and performance of the RTU solutions. The new jointly developed vial platform and trademark will be presented in detail to the market at the CPhI Worldwide Frankfurt in November.

06:07 EDT Energous's 1W WattUp PowerBridge transmitter approved in Australia, New Zealand - Energous' 1W WattUp PowerBridge transmitter has met all of the requirements set forth by the Australia Communications and Media Authority and New Zealand Radio Spectrum Management and is approved for import, marketing, and sales in the Australian and New Zealand markets. Energous' technology has received approvals over the past nine months with similar certifications in China, the U.S., Canada, Europe and India and received a recent 15W approval in the U.S. Capable of charging multiple devices simultaneously at-a-distance, Energous' 1W WattUp PowerBridges transmit RF-based wireless power over the air, enabling manufacturers to design cordless, batteryless and fully waterproof sensors, smart tags, asset trackers and other IoT applications that can be deployed in industrial, retail, enterprise, and healthcare markets.

06:06 EDT Aspen Insurance reports 1H net income $48.4M vs. $87.4M last year - Gross written premiums of $2,351.3 million in the six months ended June 30, 2022, an increase of 16.5% compared to $2,018.5 million in the six months ended June 30, 2021, primarily due to rate improvement and growth in financial and professional insurance lines, casualty and liability insurance lines and casualty reinsurance lines. Net written premiums increased by 21.8% to $1,506.1 million in the six months ended June 30, 2022, compared with $1,236.1 million in the six months ended June 30, 2021. The retention ratio in the six months ended June 30, 2022, was 64.1% compared with 61.2% in the six months ended June 30, 2021. Mark Cloutier, Group Executive Chairman and Chief Executive Officer, commented: "This is a strong set of results for Aspen with the business reporting both double digit top line growth and very healthy underwriting performance. Our year over year trends continue to show the impact of the work we have done to reshape our business and improve performance, resulting in a 6.5 percentage points improvement in our combined operating ratio to 88.2% from 94.7%. Operating income increased to $130.0 million from $66.7 million for the same period last year, representing an annualized operating return on average equity of 13.8%. "We entered the year with a well-positioned and diversified portfolio that enabled us to capitalize on positive trading conditions to grow GWP by 16.5% to $2,351.3 million. This growth came from across both the insurance and reinsurance segments and through a combination of rate increases and new business, with an average rate change across our entire portfolio of 10.9%. "Aspen Capital Partners, our capital markets franchise, is the third important pillar of our business, and we were pleased to report total fee income of $47.0 million for the six months ended June 30, 2022, an increase of $16.5 million over the prior year. Our capital markets franchise has continued to grow and now represents approximately $1 billion of AUM. Our ability to grow and diversify the capital we manage, notwithstanding a challenging environment, supports our core proposition that capital markets investors are key partners in Aspen's future growth and innovation efforts. "The Russia Ukraine conflict continues to inflict tragic, humanitarian consequences and costs. We at Aspen are doing our part to support humanitarian relief efforts during the first half of this year and on an ongoing basis. Aspen does not write primary aviation risks and, our specialty insurance exposure to the events is not significant. Although we do have specialty reinsurance exposure, we have had minimal loss notifications to date and have made provision in our first half results based upon analysis of those exposures. We continue to closely monitor the potential impact to our business. "Similar to the wider market, Aspen has seen the impact of rising interest rates result in unrealized losses in our investment portfolio. We would expect the unrealized losses to unwind as securities reach maturity, while also seeing the benefit of higher interest rates starting to impact investment income. "The trends we see in many of the key ratios and performance indicators we track give us confidence that Aspen is in a strong position to continue to benefit from attractive trading conditions we see across our markets, while at the same time continue to manage down volatility."

06:04 EDT Manchester United expands global partnership with Therabody - Manchester United and global wellness technology company Therabody have deepened their relationship by becoming global partners in a multi-year agreement. The partnership will expand Manchester United's use of Therabody products and solutions as part of the training and recovery regimes of both the men's and women's teams. Therabody's devices aim to help United's players meet the physical demands of the sport. Manchester United will have access to Theraguns in their training facilities. As part of the global partnership, players, and training staff will participate in education sessions with performance and wellness experts from Therabody University, the company's educational division.

05:49 EDT Infosys, Spirit AeroSystems enter five-year agreement - Infosys (INFY) announced a five-year agreement with Spirit AeroSystems (SPR). Infosys will collaborate with Spirit AeroSystems to provide aerostructure and systems engineering services for product development of commercial, business jet and emerging aircraft programs, and Maintenance, Repair and Overhaul, or MRO, services. This strategic collaboration builds on 16 years of longstanding relationship between the two organizations, during which Infosys has provided innovative design solutions for some of Spirit's aerostructure programs. As part of this engagement, Infosys will offer end-to-end product development services, including design engineering, sustaining engineering, systems engineering, stress engineering, manufacturing engineering, and repair and maintenance. Leveraging knowledge-based engineering and engineering automation, Infosys also aims to accelerate product development across the value stream.

05:26 EDT Zealand Pharma, Novo Nordisk enter Zegalogue license and development pact - Zealand Pharma (ZEAL) announced it has entered into a global license and development agreement with Novo Nordisk (NVO) to commercialize Zegalogue for injection. Zegalogue is approved by the FDA for the treatment of severe hypoglycemia in pediatric and adult patients with diabetes aged six and above. Under the terms of the agreement, Zealand will receive an upfront payment of DKK 25M and is eligible to receive up to DKK 45M in near-term development, regulatory and manufacturing-based milestones. Zealand is also eligible to receive up to DKK 220M in sales-based milestones and tiered royalties ranging from high single-digit to low double-digit percentages on worldwide net sales of Zegalogue to be marketed by Novo Nordisk. Zealand will be responsible for certain planned regulatory, development and manufacturing activities to support further development and approval outside of the U.S.

05:18 EDT Paysafe announces multi-state partnership with ClutchBet - Paysafe announced a partnership with ClutchBet, the new Denver-headquartered U.S. mobile sportsbook from Australia's BlueBet Holdings. The first stage of a multi-state partnership sees Paysafe's revamped Skrill USA digital wallet and its Paysafecash eCash solution facilitate online payments for ClutchBet's Iowa sportsbook and its players. Launched last month for the 2022 NFL season, the new ClutchBet sportsbook enables Iowans to wager on football, other North American sports-league games plus international sports - with the payments experience streamlined by Paysafe, which has had a presence in the Iowa iGaming market since 2020. Beyond Iowa, ClutchBet has market access agreements for its home state of Colorado plus Indiana and Louisiana, where the Paysafe payments partnership is expected to be extended going forward.

05:14 EDT Philips teams with Leiden University Medical Center, University of Pennsylvania - Philips announced a new clinical partner and highlighted clinical studies that focus on the added value of using spectral CT imaging technology during interventional procedures. Leiden University Medical Center has joined Philips' global network of clinical partners to investigate how its spectral detector angio CT solution could potentially offer new treatment opportunities and improve patient care. At this year's Cardiovascular and Interventional Radiological Society of Europe Annual Meeting, a presentation is being given by Filippo Piacentino, interventional radiologist at the University of Insubria, on the value of spectral CT imaging guidance for performing high-confidence tumor biopsies. The results being presented illustrate the potential for Philips' spectral CT technology to better guide biopsies by distinguishing between active and non-active regions in a tumor. Ensuring that a biopsy contains a high number of actively dividing cancer cells is important for high-confidence diagnosis. Philips also announced a research collaboration with the University of Pennsylvania to study the practicality of using spectral CT-based tissue temperature mapping to provide real-time feedback during tumor thermal ablation procedures to confirm its effectiveness before the patient leaves the room. This will potentially reduce the risk of localized tumor recurrence.

05:04 EDT Aurora Mobile enters push notification agreement with UP Fintech subsidiary - Aurora Mobile (JG) announced that it has signed strategic agreement with Beijing Xiangshang Yixin Technology, a subsidiary of UP Fintech (TIGR), also known as Tiger Brokers. Aurora Mobile will use its intelligent push notification service JPush to help Tiger Brokers to drive user growth and improve user experience with better asset allocation.